Evaluation and Adaptation of Live-Cell Interferometry for Applications in Basic, Translational, and Clinical Research by Leslie, Kevin A
Virginia Commonwealth University 
VCU Scholars Compass 
Theses and Dissertations Graduate School 
2018 
Evaluation and Adaptation of Live-Cell Interferometry for 
Applications in Basic, Translational, and Clinical Research 
Kevin A. Leslie 
Virginia Commonwealth University 
Follow this and additional works at: https://scholarscompass.vcu.edu/etd 
 Part of the Allergy and Immunology Commons, Biological and Chemical Physics Commons, Cancer 
Biology Commons, Cell Biology Commons, Hematology Commons, Integrative Biology Commons, 
Medical Biophysics Commons, Oncology Commons, and the Other Analytical, Diagnostic and Therapeutic 
Techniques and Equipment Commons 
 
© The Author 
Downloaded from 
https://scholarscompass.vcu.edu/etd/5562 
This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It 
has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars 
Compass. For more information, please contact libcompass@vcu.edu. 
 
 
 
 
 
 
©   Kevin Alexander Leslie             2018 
All Rights Reserved 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Evaluation and Adaptation of Live-Cell Interferometry for Applications in Basic, Translational, and 
Clinical Research 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy at Virginia Commonwealth University. 
 
 
 
 
 
 
 
 
by 
 
Kevin Alexander Leslie 
M.S. College of William & Mary, 2012 
B.S. College of William & Mary, 2009 
 
Director: Dr. Jason C. Reed 
Associate Professor, Department of Physics 
 
 
 
 
 
Virginia Commonwealth University 
Richmond, Virginia 
August 2018 
 
ii 
 
 
Acknowledgement 
No one succeeds alone.  
The end of this journey finds me indebted to a great number of people for opportunities, advice, 
inspiration, support, friendship, and love.  
Words are insufficient compensation for gifts like these. The following thanks are a small start.  
To Dr. Verrelli and Dr. Tombes, for building a program in which I could take part. Under your 
stewardship, the Integrative Life Sciences program has provided me both the financial means and 
the educational flexibility to conduct research that does not fit in the box of a single discipline. You 
have been tireless champions of every ILS student, and I am grateful for your support and 
confidence throughout my time at VCU.  
To my committee, for your support, time, and collaboration. To Dr. Manjili, my thanks for your 
time as a professor and as an advisor on grant and research strategies. To Dr. Reiner, my thanks 
for your willingness to collaborate, our discussions on optics, and the extra -80 freezer space. To 
Dr. Ryan, my gratitude for many years of mast cell discussions, strategic guidance, scientific 
integrity, and parenting advice. To Dr. Toor, a more enthusiastic physician-researcher, there is 
none. My thanks for always having an open door and time for scientific discussions and teaching, 
despite a perpetually prohibitive schedule.  
To Brian Barnstein, for providing an endless supply of mast cells, usually on short notice.  
To Dr. Catherine Roberts, for making our T cell work possible and for always asking about Henry. 
To Evelyn, for making sure everyone got what they needed when they needed it.  
To the Reed lab, for your comradery, collaboration, and comic relief.  
To Sean, for 14 years of friendship and scientific commiseration.  
To Mark, for giving me a chance, an education, and a friendship. I am forever grateful.  
To Dr. Reed, for your time and energy as a mentor and principal investigator. You have made it 
possible for me to take part in incredible research endeavors. My gratitude for your unwavering 
support of my personal goals is something I cannot adequately convey. Thank you for countless 
hours of teaching and advice, your flexibility, and the provision of key scientific and professional 
opportunities.  
To The Andersons, for providing emotional support, child care, great food, great company, and a 
willingness to tolerate a contrarian who talks too much about science.  
iii 
 
To Caroline, Katie, and Paige, for keeping me humble, making me laugh, and being incredible 
sisters and women. The world is lucky to have you.  
To my parents, for your unending love, support, and the sacrifice of time and resources to make 
sure my world is full of kindness and open doors. You will always have my love and gratitude.  
To my son, for reminding me of what is important in life. Years from now, when you stumble 
upon this work and decide to read it, know that you are a perpetual source of pride and joy.  
To my wife, for happiness. None of this would have been possible without you. Through my 
successes and failures, you have celebrated and suffered with me. You have kept our family 
afloat. I could not ask for a better partner in life. I love you!  
 
 
 
 
 
 
 
 
 
 
iv 
 
 
Table of Contents 
 
List of Figures.....................................................................................................................................vii 
List of Tables........................................................................................................................................ix 
List of Abbreviations............................................................................................................................x 
Abstract..............................................................................................................................................xii 
Chapter 1 – Cell Mass: A Versatile Biomarker.....................................................................................1 
1.0 – Chapter Overview..........................................................................................................2 
1.1 – Introduction....................................................................................................................2 
1.2 – Rationale.........................................................................................................................3 
1.3 – Techniques for Measuring Cell Mass..............................................................................4 
 1.3.1 – Non-Optical Modalities...................................................................................4 
 1.3.2 – Optical Modalities...........................................................................................6 
1.4 – Live-Cell Interferometry.................................................................................................8 
Chapter 2 – Technical Overview of Live-Cell Interferometry Systems..............................................10 
 2.0 – Chapter Overview.........................................................................................................11 
 2.1 – Original State of the VCU LCI System............................................................................11 
 2.2 – Current State of the VCU LCI System............................................................................14 
 2.3 – Image Analysis..............................................................................................................16 
 2.4 – HSLCI Platform Performance Metrics...........................................................................19 
Chapter 3 – Quantifying Melanoma Drug Resistance and Heterogeneity........................................22 
 3.0 – Chapter Overview.........................................................................................................23 
 3.1 – Introduction.................................................................................................................23 
 3.2 – Methods.......................................................................................................................29 
 3.3 – Results..........................................................................................................................30 
 3.4 – Discussion.....................................................................................................................41 
Chapter 4 – CD3+ T Cell Mass Dynamics During Stem Cell Transplantation.....................................44 
v 
 
 4.0 – Chapter Overview.........................................................................................................45 
 4.1 – Introduction.................................................................................................................45 
 4.2 – Methods.......................................................................................................................47 
 4.3 – Results..........................................................................................................................50 
 4.4 – Discussion.....................................................................................................................54 
Chapter 5 – Applications in Basic Research.......................................................................................57 
 5.0 – Chapter Overview.........................................................................................................58 
 5.1 – Apoptosis Assays..........................................................................................................58 
   5.1.1 – Introduction......................................................................................58 
   5.1.2 – Results & Discussion.........................................................................59 
   5.1.3 – Methods............................................................................................60 
 5.2 – Mast Cell Biology..........................................................................................................62  
   5.2.1 – Introduction......................................................................................62 
   5.2.2 – Approach..........................................................................................64 
   5.2.3 – Results...............................................................................................64 
   5.2.4 – Discussion.........................................................................................70 
   5.2.5 – Methods............................................................................................72 
 5.3 – Kinetics of KSHV Lytic Activation..................................................................................79 
Chapter 6 – Conclusions and Future Directions................................................................................82 
 6.0 – Chapter Overview.........................................................................................................83 
 6.1 – Summary of Work Presented.......................................................................................83 
 6.3 – Ongoing Work...............................................................................................................84 
  6.3.1 – Drug-Induced Cellular Senescence...............................................................84 
  6.3.2 – Effects of Radiation on Endothelial Cells.......................................................85 
  6.3.3 – PDX Models with HSLCI to Study Drug Resistance........................................86 
 6.4 – Future Directions..........................................................................................................92 
  6.4.1 – Three-Dimensional Cell Culture....................................................................92 
  6.4.2 – Large-Scale Patient Studies...........................................................................94 
vi 
 
 6.5 – Conclusion....................................................................................................................95 
List of References..............................................................................................................................96 
Appendix.........................................................................................................................................110 
 Supplementary Figures.......................................................................................................111 
 Supplementary Tables........................................................................................................114 
 Supplementary Methods....................................................................................................115 
 Supplementary References................................................................................................117 
Vita..................................................................................................................................................119 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
 
 
 
List of Figures 
1 – Overview of original LCI system hardware 
2 – Overview of original LCI system optics 
3 – Overview of HSLCI system hardware 
4 – Schematic of HSLCI optical hardware and accompanying ray diagrams 
5 – Example of HSLCI image processing pipeline steps 
6 – HSLCI performance overview 
7 – Overview of cell viability assays used for drug sensitivity screening 
8 – Schematic of HSLCI multi-well biomass accumulation assay 
9 – Biomass accumulation response to Vemurafenib treatment 
10 – Comparing relative mass between Vemurafenib-sensitive and -resistant isogenic lines 
11 – Vemurafenib (5 uM) sensitivity as determined by plotting pre- and post-treatment growth 
rates for Vemurafenib-sensitive (M249P) and Vemurafenib-resistant (M249R4) cell lines 
12 – Detecting resistant cells in a mixed population 
13 – Effects of kinase inhibitors on Vemurafenib-resistant melanoma as measured by HSLCI 
14 – Summary of effect of five kinase inhibitors on Vemurafenib-resistant melanoma as 
measured by HSLCI 
15 – Sample preparation and analysis procedure 
16 – Biomass of patient-derived CD3+ T cells post-transplant 
17 – Biomass and GVHD grade of patient-derived CD3+ T cells 60 and 100 days, post-transplant 
18 - Boxplots showing normalized T cell population mass distributions, over time, for two 
representative allogeneic transplant recipients 
19 – Correlation of apoptosis, PI fluorescence, and mass loss in three cancer cell Lines 
20 – Distribution of cell masses from a single mast cell population 
21 – Distinct mast cell sub-populations 
viii 
 
22 – HSLCI-measured DNP-HSA response kinetics and inter-population mass variation 
23 – Active group mass and area versus time 
24 – Correlation of Ionomycin dosing with mass loss and YoPro1 and PI Fluorescence in a single 
mast cell 
25 – RBL-2H3 cell degranulation and recovery 
26 – Proposed model of mast cell degranulation 
27 – Summary of triggering agent mechanisms of action 
28 – LCI sample mount and dosing overview 
29 – Single-cell Doxycycline-induced KSHV lytic activation 
30 – Overview of PDX model generation and usage 
31 – Patient-derived xenograft (PDX) lines PT52 and HCI09 sensitivity to Carboplatin 
32 – Single-cell example of PT52 Carboplatin response heterogeneity 
 
 
 
 
 
 
 
 
ix 
 
 
List of Tables 
1 – Patient Demographics 
 
 
 
 
 
 
 
 
 
 
 
 
x 
 
 
List of Abbreviations 
2D...............................................................................................................................two dimensional 
3D.............................................................................................................................three dimensional 
aGVHD.................................................................................................acute graft versus host disease 
ASCO........................................................................................American Society of Clinical Oncology 
ATP..................................................................................................................adenosine triphosphate 
AUC.....................................................................................................................area under the curve 
BMMC................................................................................................bone marrow mononuclear cell 
BRAFi..............................................................................................................................BRAF inhibitor 
CCD...................................................................................................................charge-coupled device 
CD3.............................................................................................................cluster of differentiation 3 
CD8.............................................................................................................cluster of differentiation 8 
cGVHD..............................................................................................chronic graft versus host disease 
Cmax............................................................................................peak measured serum concentration 
CMV............................................................................................................................cytomegalovirus 
CO2................................................................................................................................carbon dioxide 
CV.....................................................................................................................coefficient of variation 
ddCD3.....................................................................................................................donor-derived CD3 
DHM....................................................................................................digital holographic microscopy 
DMEM..........................................................................................Dulbecco's Modified Eagle Medium 
DMSO......................................................................................................................dimethyl sulfoxide 
DNA....................................................................................................................deoxyribonucleic acid 
DNP-HSA..........................................................................................................Human Serum Albumin 
EBV............................................................................................................................Epstein Barr virus 
ELISA.........................................................................................enzyme-linked immunosorbent assay 
xi 
 
ER.............................................................................................................................estrogen receptor 
FDA.......................................................................................................Food and Drug Administration 
fps...........................................................................................................................frames per second 
GFP..............................................................................................................green fluorescent protein 
GPU ...............................................................................................................graphics processing unit 
GVHD.............................................................................................................graft versus host disease 
GWAS.................................................................................................genome-wide association study 
Gy...................................................................................................................................................Gray 
HER2................................................................................human epidermal growth factor receptor 2 
HHV-8..................................................................................................................human herpesvirus 8 
HLA...............................................................................................................human leukocyte antigen 
HSLCI.............................................................................................high-speed live-cell interferometry  
IgE............................................................................................................................immunoglobulin E 
IL-3....................................................................................................................................interleukin 3 
IL-6....................................................................................................................................interleukin 6 
KS...............................................................................................................................Kaposi's sarcoma 
KSHV....................................................................................Kaposi's sarcoma-associated herpesvirus 
LCI....................................................................................................................live-cell interferometry 
LED........................................................................................................................light-emitting diode 
MMF................................................................................................................mycophenolate mofetil 
MRD.................................................................................................................matched related donor 
MTT...................................................3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide 
MTX.................................................................................................................................methotrexate 
MUD............................................................................................................matched unrelated donor 
NA..........................................................................................................................numerical aperture 
NOD........................................................................................................................non-obese diabetic 
NRM...................................................................................................................non-relapse mortality 
xii 
 
OPD..................................................................................................................optical path difference 
PCS.....................................................................................................................pluripotent stem cells 
PDX..............................................................................................................patient-derived xenograft 
PI................................................................................................................................propidium iodide 
PR.....................................................................................................................progesterone receptor 
PRS...............................................................................................................pedestal resonant sensor 
PSI..........................................................................................................phase-shifting interferometry 
QPI.............................................................................................................quantitative phase imaging 
QWLSI............................................................................quadriwave lateral shearing interferometry 
RFP...................................................................................................................red fluorescent protein 
RNA..............................................................................................................................ribonucleic acid 
ROC..................................................................................................Receiver Operator Characteristic 
RPMI..................................................................................................Roswell Park Memorial Institute 
SCF................................................................................................................................stem cell factor 
SCID............................................................................................severe combined immunodeficiency 
SCT.........................................................................................................................stem cell transplant 
SD............................................................................................................................standard deviation 
SLIM...........................................................................................spatial light interference microscopy 
SMR.............................................................................................suspended microchannel resonator 
SNP....................................................................................................single-nucleotide polymorphism 
SSD..............................................................................................................................solid-state drive 
TNBC.......................................................................................................triple-negative breast cancer 
UCLA..........................................................................................University of California - Los Angeles 
VCU...............................................................................................Virginia Commonwealth University 
YP1.............................................................................................................................................YoPro1 
 
xiii 
 
 
Abstract 
EVALUATION AND ADAPTATION OF LIVE-CELL INTERFEROMETRY FOR APPLICATIONS IN BASIC, 
TRANSLATIONAL, AND CLINICAL RESEARCH 
By Kevin Alexander Leslie, M.S. 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy at Virginia Commonwealth University 
 
Virginia Commonwealth University, 2018 
 
Major Director: Dr. Jason Reed, Associate Professor, Department of Physics 
 
Cell mass is an important indicator of cell health and status. A diverse set of techniques have 
been developed to precisely measure the masses of single cells, with varying degrees of 
technical complexity and throughput. Here, the development of a non-invasive, label-free optical 
technique, termed Live-Cell Interferometry (LCI), is described. Several applications are 
presented, including an evaluation of LCI’s utility for assessing drug response heterogeneity in 
patient-derived melanoma lines and the measurement of CD3+ T cell kinetics during 
hematopoietic stem cell transplantation. The characterization of mast cells during degranulation, 
the measurement of viral reactivation kinetics in Kaposi’s Sarcoma, and drug response studies in 
patient-derived xenograft models of triple-negative breast cancer are also discussed.  Taken 
together, data from these studies highlight LCI’s versatility as a tool for clinical, translational, and 
basic research applications.  
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Chapter 1 
Cell Mass: A Versatile Biomarker 
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1.0 Chapter Overview 
This chapter provides a brief overview of cell mass, including its relevance as an indicator of cell 
health, and techniques with which it can be measured. Cell mass is the common thread woven 
through all of the experiments described in this dissertation, and the sections that follow aim to 
orient the reader to this important intersection of single-cell biology and physics.  
1.1 Introduction 
Cell growth and proliferation are tightly regulated but incompletely understood processes.1,2 In 
unicellular organisms like bacteria, they are generally governed by resource availability in the 
extracellular environment.3 For multicellular organisms, comprised of varying tissue types and 
proceeding through multiple stages of development, a more complex and coordinated system of 
signaling is required to maintain homeostasis.4,5 This system, enabling individual cells to monitor 
and change or maintain their size, relies on a combination of molecular gradients within the cells 
themselves, mechanical signals from the extracellular environment, and paracrine and endocrine 
signaling.6,7,8,9 Further, as cells can grow (accumulate mass) without dividing, it is important to 
appreciate that these two processes, cell growth and cell division, can be differentially 
regulated.1  
A human’s survival and reproduction depends on the continuous and appropriate regulation of 
cell growth and proliferation. Injuries to the skin must be rapidly repaired, immune cell 
populations must expand in response to infection, egg cells must remain viable for decades, and 
muscles must adapt to mechanical demands. Even cells that appear quiescent can be quite 
dynamic, striking a delicate metabolic balancing act by exhibiting levels of biosynthesis identical 
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to growing or proliferating cells while simultaneously having higher levels of protein 
degradation.10 However, when this system of regulated cell growth and division breaks down, 
disease often results. Hearts can become enlarged, cancer can develop, and developmental 
brain disorders can occur.11–13 
The work described herein focuses on measuring the mass of a variety of human cells to 
understand how their growth and division are impacted by different stimuli, including cytotoxic 
drugs. In turn, this information could allow us to better understand basic biological processes, 
predict drug efficacy, and even modulate therapeutic regimens for cancer patients.  
1.2 Rationale 
A red blood cell weighs just 27 picograms, on average, while an ovum can be 100,000 times 
heavier, exceeding 3.5 micrograms.14  Neutrophils, important components of the immune 
system, are renewed on an almost daily basis, while neurons of the cerebral cortex can last a 
lifetime.15,16 This kind of dynamic range implies a corresponding heterogeneity in rates of mass 
accumulation and division among human cell types.17 Logically, as common processes like 
apoptosis (controlled cell death), growth, and division all encompass changes in cell size or 
protein synthesis, cells should exhibit mass kinetic signatures that correspond with these 
events.18 This should also hold true for cell type-specific functions like activation in T cells or 
degranulation in mast cells.19–23 Taken further, significant dysregulation or disruption of any of 
these processes should be detectable as a change in these kinetic signatures.  However, 
accurately characterizing baseline cell growth and, subsequently, detecting these kinetic 
signatures requires the ability to non-invasively measure cell mass with picogram sensitivity. 
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Within the last 15 years, significant progress has been made on this front, seeing the advent of 
multiple measurement platforms capable of achieving single-cell resolution. These techniques 
and their subsequent applications are discussed in the sections that follow.  
1.3 Techniques for Measuring Cell Mass 
Cellular biomass can be measured using a variety of techniques, including biochemical stains, 
mass spectrometry, electron microscopy, various forms of interference microscopy, and 
microbalances.24–50 However, most have seen limited use in clinical or research settings due to 
their technical complexity, inadequate throughput, or limited precision.51–53 For the purposes of 
this discussion, only techniques capable of measuring mass in living cells over time with 
picogram precision will be considered; they will be categorized as either optical or non-optical 
modalities.  
1.3.1 Non-optical modalities 
Non-optical modalities rely on indirect physical measurements to determine the mass of a cell. 
The two most common are Suspended Microchannel Resonators (SMRs) and Pedestal Resonant 
Sensors (PRSs). While these techniques can often be more precise than optical approaches, their 
low throughput and inability to handle a variety of cell types (i.e. adherent and non-adherent, 
clumps and single cells) tend to be limiting factors to their broad-scale adoption.  
Suspended Microchannel Resonators 
Suspended microchannel resonators derive the mass of a cell by measuring changes in the 
vibrational frequencies of a silicon cantilever.54 Briefly, the cantilever contains a small channel 
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through which liquid and particles or cells can flow. This cantilever is vibrated at multiple 
frequencies and, using small piezoresistors embedded in the silicon surface or an external laser 
doppler vibrometer, these vibrations are recorded.55 As a cell passes through the microchannel, 
a detectable alteration of vibrational patterns is induced. These patterns can be used to derive 
the buoyant mass of a cell. SMRs have been used successfully to measure a range of bacteria, 
yeast, and mammalian cell types.56  
The newest iteration of this technique involves arraying multiple SMRs in a serial fashion, 
allowing the measurement of the same cell multiple times over the course of 15 minutes with a 
precision of 50 femtograms; cells remain viable after passing through the channel. This setup has 
been used to correlate drug-induced changes in single-cell growth rates in myeloma cells to drug 
responses in several patients.57 However, SMRs are currently limited to analyzing 60-120 cells 
per hour.58 In order to detect rare cells in a heterogeneous population or conduct screens on 
multiple therapeutics simultaneously, a significant increase in throughput is required.  
Pedestal Resonant Sensors (PRS) 
Pedestal resonant sensors (PRS) operate similarly to SMRs. Briefly, the devices consist of an array 
of small sensors (60 x 60 μm2) each suspended by a set of four nanoscale springs (80 μm x 4 
μm).59,60 Single cells are deposited on, and subsequently attach to, these sensors. A laser doppler 
vibrometer measures the resonant frequencies of these sensors, over time, in the presence of 
the living cells. As cells change their mass, they detectably alter the resonant frequency of the 
sensor to which they are attached. From these resonant frequency changes, cell mass can be 
derived. Despite an ability to accurately measure cell mass over many hours, PRSs are not 
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compatible with fluorescence microscopy, preventing correlative studies.56 Like SMRs, PRSs 
suffer from low throughput (<100 cells measured simultaneously). In addition, adherent cells 
often migrate off the sensor pedestals, complicating the process of tracking single cells for 
multiple days.61  
1.3.2 Optical modalities 
Quantitative optical mass measurements of single living cells began in the 1950s48,62 and, thanks 
to advances in both digital imaging technology and computing power, newer approaches have 
increased in speed, precision, and practicality.26,27  
In their most basic form, optical mass measurements of cells can be acquired using Michelson-
style interferometry, which involves the extraction of information from the superimposition of 
two light beams that have traveled separate paths after being split from a single illumination 
source. The first beam passes through a target object (i.e. a cell), while the second (“reference”) 
beam passes through a material that simulates the optical path of the first, without the target 
object. Re-combination of these two beams yields an interference pattern from which the mass 
of the target can be derived. Specifically, the interference pattern is a result of the differing 
lengths of the optical paths (a product of the medium’s index of refraction and the geometric 
length of the light’s path) between the two beams. The dense material in the target cell, through 
which the first beam passes, increases the optical path length of the beam. When these path 
length differences are calculated across the entire area of a target object, the optical density of 
the object can be calculated. Optical density can be converted into dry mass by applying a 
whole-cell-average dry mass ratio based on the average refractive indices of biological molecules 
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(e.g., protein, DNA, RNA).46 Our group’s original live-cell interferometry platform utilized phase-
shifting interferometry (PSI) which operates using the basic principles outlined above. However, 
PSI also uses a piezoelectric transducer to rapidly introduce path length changes in one arm of 
the Michelson-style setup during image collection, resulting in the generation of multiple 
interferograms that enable the enhanced resolution of optical path differences.63 
Variations on this technique have yielded an array of quantitative phase imaging (QPI) 
microscopy platforms for the examination of biological specimens.56,64 A notable example is 
digital holographic microscopy (DHM), wherein a laser light source is used to generate 
holograms of living cells, enabling the reconstruction of three-dimensional images.65 The 
technique, like all QPI-based modalities, requires no cell staining or labeling. It is also, uniquely, 
afocal, as images can be digitally autofocused (within a range limited by the numerical aperture 
of the microscope objective) after collection depending on the z-dimension layer of interest. 
However, current implementations suffer from high noise as a result of multiple reflections and 
laser speckling inherent to DHM.66 In addition, though DHM’s use of laser illumination poses 
problems for long-term imaging of biological samples due to risks of phototoxicity, this can 
generally be mitigated by using lower intensities or longer wavelengths.67 
A low-noise alternative to DHM is quadriwave lateral shearing interferometry (QWLSI).26 In this 
QPI variant, non-laser coherent light passes through living cells and is then sheared by a 
diffraction grating into multiple replica wavefronts. These wavefronts combine to produce an 
interference pattern that yields dry mass data on the target cells. Typically, this process is 
condensed into a single camera unit, wherein the diffraction grating is fixed several millimeters 
from the camera’s CCD sensor (on which the interference pattern is produced and recorded). 
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This modular camera approach enables the technique to be easily incorporated into existing 
microscopy platforms and used in parallel with fluorescence techniques.  
Recent applications of quantitative phase microscopy using other imaging platforms include 
measurements of cell growth, cell death, membrane mechanics, individual organelles, and 
preliminary imaging studies of mouse pluripotent stem cells (PSCs).60,68–71 Emerging translational 
uses of the technique are highly promising, including its use in characterizing tissue 
inflammation, wound healing, and circulating tumor cells.72–74 
1.4 Live-Cell Interferometry (LCI) 
Prior to the initiation of the work described herein, Reed et al. utilized early versions of an optical 
single-cell mass measurement technique, termed live-cell interferometry (LCI), to investigate a 
broad range of biological processes. Based on a Michelson-style phase-shifting interferometer, 
early LCI platforms were precise but low-throughput, capable of measuring single cells with 
picogram sensitivity and CV’s less than 1%, but slowed down by required focusing and image 
collection times.  
Initially, LCI was used to address questions in basic biology, such as the quantification of 
cytoskeletal rearrangements in NIH/3T3 embryonic fibroblasts in response to mechanical 
stimulation.75 Later studies focused on the appropriation of mass between daughter cells during 
cell division, as well as the motility and distribution of mass in undifferentiated versus 
differentiated human stem cell colonies.76,77  
Applications eventually expanded to include the characterization of drug responses in a variety 
of human cancer lines. Experiments using H929 multiple myeloma cells demonstrated the LCI’s 
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ability to determine sensitivity to Tunicamycin in several hundred individual cells by measuring 
cell mass over time.78 This was followed by a similar set of experiments using Trastuzumab and 
four breast cancer cell lines of varying HER2 statuses and clustering behaviors.25 Taken together, 
these studies highlighted LCI’s ability to measure drug sensitivity in both adherent and non-
adherent cell types, as well as single cells and/or cell clusters. This versatility remains one of LCI’s 
fundamental advantages. However, at the time, the LCI’s throughput was a major limiting factor 
in expanding to new translational research projects and improving its utility for existing 
applications.  
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Chapter 2 
Technical Overview of Live-Cell Interferometry Systems 
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2.0 Chapter Overview 
This chapter provides hardware and performance descriptions of the original LCI system and its 
high-speed successor, the HSLCI (High-Speed Live-Cell Interferometry) system. The sections that 
follow provide technical context for the diverse range of applications described in later chapters.  
2.1 Original State of the VCU LCI System 
In 2012, the original VCU LCI system utilized phase-shifting interferometry63 and consisted of a 
combination of two motorized linear translation stages, one small stepper motor, one flexure 
stage, a CCD camera, a single LED illumination source, and a custom Michelson interferometric 
imaging head. It was situated on a vibration isolation table and was not enclosed. A schematic 
and image of the system are shown in Figure 1. 
The core of this system was the interferometer head (Figure 2). Briefly, 660 nm collimated light 
from a fiber-coupled LED source (Thorlabs, Inc.) enters the rightmost side of the head unit. This 
light is split by a beam splitter into two beams: a reference beam and a sample beam. The 
sample beam is directed towards the sample (containing beads or cells). The reference beam is 
directed through a reference cell designed to mimic the optical path of the sample beam, minus 
the actual sample. This reference cell is composed of two pieces of glass mounted in a small 
aluminum block, separated by 700 μm steel spheres, and filled with distilled deionized water. 
After passing through the reference cell, the reference beam encounters a mirror (whose 
position is adjustable) and reflected back towards the original beam splitter. Both the reference 
and sample beams are reflected (and subsequently recombined) towards the CCD camera after 
re-encountering the beam splitter. The retardation of the sample beam relative to the reference 
12 
 
beam, caused by the higher index of refraction of the material encountered in the sample 
objects, results in the generation of interference patterns in the light reaching the CCD camera. 
In order for this technique to work, the interferometric head’s mirror must be positioned with 
micrometer precision so that the lengths of the geometric paths traveled by both the sample 
and reference beams are identical. Additionally, the sample’s tilt must be corrected so that the 
objects being imaged are parallel to the imaging lens. Reference mirror positioning was 
accomplished manually using an external rotary knob mounted to the side of the interferometer 
head.  Tilt correction was automatically performed using a stepper motor controlled by a custom 
MATLAB script; a three-axis flexure stage (NanoMax-TS, Part# MAX301, Thorlabs, Inc.) enabled 
rapid Z-direction adjustments for phase shifting. Sample navigation was performed using two 
linear stepper motors (NRT100, Thorlabs, Inc.). Images were collected using a CCD camera 
coupled to a Mitutoyo VMU and 40X objective lens. 
Figure 1. Overview of original LCI 
system hardware. Optical 
components are arranged to form a 
Michelson interferometer (the fixed 
interferometer head contains the 
reference arm and beam splitter). 
Stepper motors and a flexure stage 
are controlled using a custom 
MATLAB interface and enable 
sample navigation, focusing, and tilt 
correction. Coherent light is 
provided by an LED. A black and 
white CCD camera collects images. 
The entire system rests on a 
vibration isolation table to minimize 
noise.  
13 
 
Samples were deposited onto 20 mm x 20 mm hand cut pieces of silicon wafer, submerged in 
culture media, in one of four wells in a custom Teflon block. Custom “optical windows,”  
  
consisting of 28.6 mm stainless steel rings coupled to optical glass and supported by three 700 
μm stainless steel spheres, were then placed on top of the silicon wafers.  
Figure 2. Overview of original LCI system optics. Collimated light from a fiber-coupled LED 
source enters the rightmost side of the head unit. This light is split by a beam splitter into 
two beams: a reference beam (blue) and a sample beam (green). The sample beam is 
directed towards the sample (containing beads or cells). The reference beam is directed 
through a reference cell designed to mimic the optical path of the sample beam, minus the 
actual sample. After passing through the reference cell, the reference beam encounters a 
mirror (whose position is adjustable) and reflected back towards the original beam splitter. 
Both the reference and sample beams are reflected (and subsequently recombined) towards 
the CCD camera after re-encountering the beam splitter. 
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All sample navigation and image collection was performed and triggered using manual 
micrometer manipulation combined with stepper motor movement and image acquisition 
controlled through a simple MATLAB graphical user interface (GUI). Capturing a single 2 x 2 grid 
of images required approximately 90 seconds.  
After collection, images were processed using a combination of custom MATLAB scripts, 
described previously by Reed et al. to unwrap the acquired phase images and calculate phase 
shifts.78 Computed phase images were “flattened” by correcting for low-frequency background.  
Single cells were segmented from the background of the flattened phase images using a spatial-
derivative edge detection kernel; their locations and optical volumes were recorded. Frame-to-
frame cell tracking was accomplished with a previously-described particle tracking algorithm.78  
Single-cell growth tracks were generated for each object tracked and then plotted as optical 
volume versus time. Performance of the system in this state was slow but robust, with data 
revealing coefficients of variation (CV) less than 0.5% and picogram sensitivity.  
2.2 Current state of the VCU LCI System 
The current high-speed live-cell interferometry (HSLCI) platform consists of a custom-built 
inverted optical microscope coupled to a quadriwave lateral shearing interferometric camera 
(SID4BIO, Phasics, Inc.).26,79,80 The camera consists of a 1600 x 1200 pixel CCD camera (B1621, 
Imprex, Inc.) fitted with a modified Shack-Hartman mask. It is self-referencing, simple to mount, 
and capable of recording at 30 fps. The SID4BIO’s flexibility and image acquisition efficiency 
ultimately precipitated its replacement of the LCI’s original interferometer head. Cells are 
imaged in single, standard-footprint (128 mm x 85 mm), glass-bottomed, multi-well plates. 
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Acquired images are analyzed in near real-time by a downstream PC (Dell Precision Tower 5810). 
All of the platform’s hardware and software components are available commercially. A basic 
schematic of the HSLCI system is provided in Figure 3.   
Briefly, a multi-well plate holder coupled to three linear translation stages enables automated 
sample movement in three dimensions during image acquisition. The scale of topographical 
variation within and between multi-well plates necessitates a flexible and robust focusing 
scheme (Supplementary Figure 1). Best focus is rapidly and consistently maintained during lateral 
scanning using a custom-built automatic feedback loop consisting of a coaxial optical beam 
deflection position sensor coupled to a one-dimensional piezo stack on which the microscope 
objective is mounted. The sample is illuminated using a 660 nm LED light source that is 
collimated and then strobed to coincide with the SID4BIO camera’s exposure, using a SID4BIO-
generated trigger, at a rate of 4 fps. After passing through the sample, the light is magnified by 
an objective lens and directed to both the SID4BIO and a wide-field CCD camera (acA645-100, 
Basler AG) utilized for correlative and fluorescent imaging (Figure 4). Either a 40X objective(Nikon 
Plan Fluorite, NA 0.75), 20x objective (Nikon Neofluar, NA 0.5 or Nikon Plan Fluorite, NA 0.3) or a 
10x objective (Nikon Plan Fluorite, NA 0.3) were used for the growth kinetics and population 
studies described herein, depending on the desired size of the field of view. The entire HSLCI 
platform is installed inside a standard cell culture incubator (Steri-Cult CO2 Incubator, 
ThermoFisher) to maintain the environmental conditions necessary for cell viability. 
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2.3 Image Analysis 
Briefly, raw interferograms acquired by the SID4BIO are converted to phase images using the 
manufacturer’s software and then analyzed with our custom MATLAB (Mathworks, Inc.) scripts. 
The phase calculation down-samples the raw interferogram image to 400 x 300 pixels, resulting in 
effective pixel sizes between 1.3 μm and 2.5 μm, depending on the objective.  
Figure 3. Overview of HSLCI system hardware. A 24-well plate containing samples for 
imaging is secured in a custom stage. The sample is illuminated from above using collimated 
light from an LED. Three stepper motors enable stage movement in X, Y, and Z directions for 
sample navigation. The focusing module uses a feedback loop to maintain a fixed distance 
between the objective and the plate bottom during imaging. The epifluorescence module 
provides illumination for the excitation of fluorophores. The image collection module is 
comprised of the Phasics QWLSI camera for the collection of interferograms and a color CCD 
camera for the collection of brightfield and fluorescent images. Mirrors are represented by 
solid green lines and dichroics are represented by double green lines. 
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The intensity signal across the phase image matrix is deconvolved in the Fourier domain around 
the spatial period of the diffraction grating to generate an unwrapped phase image. This a phase 
gradient that is then numerically integrated to derive the optical path difference. The optical path 
difference (OPD) is defined as a function of the spatial position in the wavefront.  
𝑂𝑃𝐷(𝑥, 𝑦) = ∫ [𝑛(𝑥, 𝑦) − 𝑛𝑚𝑒𝑑𝑖𝑢𝑚]𝑑𝑧
ℎ
0
 
Here, n is the refractive index of the specimen and nmedium is the refractive index of the medium.  
 
The difference is integrated over the total thickness h in the direction of propagation. As the 
resulting value is a combination of OPD from the sample and the OPD from the imaging system, a 
Figure 4. Schematic of HSLCI optical hardware and accompanying ray diagrams. Samples are 
imaged in standard-footprint multi-well plates. Phase images are collected by an off-axis 
QWLSI camera. Best focus is maintained using a feedback loop to measure the distance (f) 
between the multi-well plate’s bottom and the microscope objective. Changes in f are 
detected using an infrared laser and quadrant photo diode (QPD). A piezo actuator 
coupled to the objective compensates for any detected change by adjusting the position 
of the objective in the z direction. (Adapted from Guest, D. 2017) 
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reference image is captured prior to imaging the sample; we eliminate any contribution from the 
imaging system by subtracting the reference image. The OPD is then used to derive the optical 
volume difference OVD, wherein the OPD is integrated over the total imaging surface (S). Hence, 
𝑂𝑉𝐷 = ∬ 𝑂𝑃𝐷(𝑥, 𝑦)𝑑𝑥𝑑𝑦 
 
𝑆
 
This value is directly proportional to the dry mass of the cell (referred to herein as “biomass”) by 
a constant known as the specific refractive increment α. The specific refractive increment is the 
rate of change in the refractive index n of a specific specimen.  
∬ 𝑂𝑃𝐷(𝑥, 𝑦)𝑑𝑥𝑑𝑦 =  𝛼 ∙ 𝑚
 
𝑆
 
This can be rearranged as 
𝑚 =
1
𝛼
𝑆 ∙ 𝑂𝑃𝐷 
to find the mass (m), where S is the surface area of the specimen in microns. For the experiments 
described herein, 
1
𝛼
 is equal to 5.56 
𝑝𝑔
𝑢𝑚3
 .48 
Computed phase images are “flattened” by correcting for low-frequency background noise 
inherent to the shearing interferometry method.  Single cells are segmented from the background 
of the flattened phase images using a spatial-derivative edge detection kernel; their locations and 
optical volumes are recorded. An example of step-wise images from this process is provided in 
Figure 5. 
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Frame-to-frame cell tracking is accomplished with a previously-described particle tracking 
algorithm.78  Single-cell growth tracks are quality filtered using an upper cutoff of +/-15% 
uncertainty (SD of residuals) in the calculated growth rate, as determined by linear fitting the dry 
mass versus time data.  
2.4 HSLCI Platform Performance Metrics 
In its current configuration, the HSLCI system can, at a minimum, collect and process 960 images 
from as many unique locations in a multi-well plate every 10 minutes, yielding biomass data on 
at least 103– 104 individual cells.  Due to the mechanical and environmental stability of the HSLCI 
system, we have been able to track single cells and cell clusters for up to 10 days, with no time 
limit yet found.  The HSLCI’s stages enable lateral scanning at a maximum velocity of 2mm per 
second, while the SID4BIO camera is capable of capturing data at rates up to 30 fps. For a 24-
well plate, even at a capture rate of 4 fps, this translates to only 2.5 minutes needed to acquire 
240 unique images (40 images/well) in a single six-well column. After acquisition, deriving a 
phase image from a single raw interferogram typically requires 500 ms, while the remainder of 
post-processing  (flattening, cell segmentation, and cell tracking) typically requires 500-1,000 ms, 
on a single Intel Core i7 processor. Compared to our prior implementations, our current pipeline 
conducts image processing as soon as images are acquired and parallelizes these steps across 
eight or more processors on a single high-performance PC, resulting in near real-time processing. 
An overview of the HSLCI imaging and data analysis pipeline is provided in Figure 6. 
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Figure 5. Example of HSLCI image processing pipeline steps. Images shown are of the same location 
at three different time points. Brightfield and fluorescent images were collected with a Basler color 
CCD camera and did not undergo processing after acquisition. Interferograms were collected by a 
Phasics QWLSI camera and were subsequently converted into unwrapped phase images, flattened, 
and segmented to yield mass data for single cells. 
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Figure 6. HSLCI performance overview. Prior to imaging, cells and media (including drug or 
vehicle) are dispensed into standard-footprint, glass-bottomed multi-well plates. During 
imaging, the sample plate is translated along each row of wells, collecting 30 images per well 
on each pass. Following collection, phase images are automatically analyzed in a custom 
pipeline that includes background flattening, cell detection and segmentation, and biomass 
calculation. Individual cells are tracked between images based on their position, and biomass 
versus time plots are generated.   
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Chapter 3 
Quantifying Melanoma Drug Resistance and Heterogeneity 
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3.0 Chapter Overview 
This chapter details the deployment of HSLCI during a multi-year study on drug resistance and 
heterogeneity in patient-derived melanoma cell lines. This project was planned and executed in 
close collaboration with the Dr. Michael Teitell’s laboratory at the University of California – Los 
Angeles (UCLA). The text and figures that follow have been adapted (reproduced with permission 
of The American Chemical Society and co-authors) from a publication of the study’s results, co-
first authored by K. Leslie and D. Huang, in the journal Analytical Chemistry.81   
3.1 Introduction 
An estimated 91,270 new cases of cutaneous melanoma with 9,320 deaths will occur for the 
United States in 2018.82 Despite comprising less than 2% of skin cancer diagnoses, melanoma is 
responsible for 75% of skin cancer deaths.83 Genetic landscape studies show inter-patient, intra-
patient, and intra-tumor heterogeneity. About 50% of melanomas harbor an activating mutation 
in the BRAF gene, whereas 10-25% of cases show an activating RAS mutation, 12-18% are 
mutant in NF1, and 7-28% of tumors show mutations in genes that include AKT and PTEN.  Most 
of these mutations increase MAPK pathway signaling activity, which regulates cell proliferation, 
differentiation, and survival.84–87 Targeted therapies, most notably against BRAF V600E and 
V600K activating mutations, have improved progression-free survival for many melanoma 
patients.88 However, therapy resistance emerges in most cases of BRAF or MEK inhibitor 
monotherapy, often from preexisting or acquired mutations that reactivate the MAPK pathway 
downstream of the drug-targeted site.89 Current BRAF and MEK inhibitor combination therapies 
aim to reduce the frequency of emergent resistance.90,91 Drug selection guidance comes from 
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clinical tumor staging, mutation screening, patient health, and prognostic factors such as lactate 
dehydrogenase levels.92 Despite multifactorial guidance, resistance eventually develops even for 
up to 80% of patients receiving combination therapy.88 Genetic heterogeneity underlying 
mechanisms of preexisting and acquired resistance makes mutation screening incompletely 
predictive of drug susceptibility, both prior to the start of therapy and after the development of 
resistance, and increases the difficulty of selecting efficacious frontline and second-line 
therapies.93–95 
Current efforts in repeat tumor assessment focus on noninvasive liquid biopsy methodologies 
such as the detection and analysis of circulating exosomes, microRNAs, circulating tumor DNA, 
circulating tumor cells, and proteomic profiling of serum proteins by mass spectrometry.96,97 
While samples from the circulation provide easily accessible materials that may be more 
representative of a patient’s tumor heterogeneity than single-site tumor biopsies, there are 
presently no reliable molecular biomarkers from circulation sampling to guide targeted 
melanoma therapy or improve outcome predictions.98–100 Other limitations include a lack of 
standardization, low sample yields, and the high cost of post-isolation analyses, which makes 
many circulation-sampling methods impractical for broad-scale clinical implementations in their 
present state.101,102  
An alternative to circulating biomarkers is the in vitro measurement of drug responses in excised 
tumor cells using chemosensitivity assays, such as ATP quantification or assessments of cell 
metabolic activity.103–106 Advocated by major cancer centers and international research 
organizations, such as the American Society of Clinical Oncology (ASCO), chemosensitivity assays 
have seen minimal adoption in melanoma treatment. This is due to long, three-to-seven day 
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turnaround times that increase the likelihood of artifacts, a lack of supporting large-scale 
clinical trials, and interference from heterogeneous co-harvested tumor elements (such as 
stromal fibroblasts) that often overrun cultures and may result in false or misleading data. 107–
111 Further, the most popular cell death assays using ATP or MTT measurements are bulk 
methods, which is a significant limitation for typically-heterogeneous cancers, especially given 
that growth arrest and senescence (rather than sudden cell death) are common drug responses 
and resistance mechanisms.108,111–114 By contrast, acute cell killing assays can provide data at a 
snapshot in time using fresh tissue, but have not proven sufficiently informative as stand-alone 
assays.115–119 
High-content screening systems based on confocal microscopy, such as the commercially-
available GE In Cell Analyzer (General Electric, Inc., Boston, MA)and Yokogawa CV8000 
(Yokogawa Electric Corporation, Tokyo, Japan) platforms, were introduced as a versatile 
solution to many of these problems through their combined use of automation, environmental 
controls, and compatibility with a variety of assays. Unfortunately, these systems still require 
that cells be labeled for chemosensitivity and cytotoxicity testing. A superior, high-throughput, 
reproducible, standardized, and inexpensive approach to determine drug sensitivity before 
(and periodically during) therapy is, therefore, desirable.   
A variety of in vitro and ex vivo methodologies have emerged to address the shortcomings of 
these traditional cell viability assays in the context of personalized cancer care (Figure 7). 
Specifically, newer strategies have focused on reductions in turnaround time and sample 
quantity via microfluidics, a more accurate simulation of the tumor microenvironment, and 
novel non-genetic biomarkers of drug sensitivity.120–122 Despite progress in these areas, the 
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field has not yet achieved the required combination of accuracy, throughput and single-cell 
sensitivity needed for predictive assays to guide cancer treatment selection 
We have previously shown that optical interferometric microscopy provides an exciting potential 
solution by profiling drug-induced growth arrest in living single cells or cell clumps via changes in 
biomass over time with picogram sensitivity.25,78 However, this proof-of-principle work consisted 
of single agent, small-scale studies of limited duration.  The key remaining engineering challenge 
is to create a reliable platform for multi-agent, multi-concentration parallel screens without 
sacrificing measurement accuracy or assay acceleration.  Meeting this challenge 
 
requires, at a minimum, an order of magnitude increase in the number of different conditions 
tested within a single experiment, and a corresponding increase in the number of individual cells 
analyzed per hour.   This is a sizable hurdle, for a variety of methodological reasons, but is 
Figure 7. Overview of cell viability assays used for drug sensitivity screening. The majority 
(93%) of viability assays require the use of one or more labeling molecules to assess cell 
growth or viability. Of the label-free methodologies, only quantitative phase imaging has 
demonstrated throughput comparable to label-based techniques while maintaining single-
cell resolution.    
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absolutely required to enable practical, rapid response profiling of patterns of drug resistance, 
intra-tumor heterogeneity and for ultimately developing a reproducible therapy selection 
method.   
To reach this goal, we created and deployed the HSLCI (Figure 8).  HSLCI’s dynamic focus 
stabilization enables continuous image collection over the entire sample area without pause, and 
stage-top or whole microscope enclosures provide long-term environment stability for imaging 
under physiology-approximating conditions (37 oC, 5% CO2).  The HSLCI captures images from 
standard format, glass bottom multi-well cell culture plates and each well can contain a different 
cell type exposed to a unique drug dose or combination.  The experiments described here 
utilized 4-well and 24-well glass bottom plates, although well counts of up to 96 are possible 
depending on the experimental conditions, including cell concentration, population sampling 
depth, required temporal resolution, and other parameters. This present work describes a two-
center study using HSLCI to quantify biomass kinetics for three isogenic sensitive/resistant pairs 
of patient-derived, V600EBRAF mutant melanoma cell lines in response to the BRAF inhibitor 
(BRAFi), Vemurafenib, and a battery of FDA-approved kinase inhibitors.  We show that HSLCI-
quantified biomass kinetic signatures during 24 hours of drug exposure discriminates between 
drug-sensitive and drug-resistant tumor subpopulations.  HSLCI data are reproducible between 
study sites and consistent with longer multi-day growth inhibition assays.   
Of particular practical importance for any future clinical laboratory use is HSLCI’s compatibility 
with pre-sterilized, disposable, and standard format multi-well sample plates.  This enables 
28 
 
 
efficient screening of multiple drugs and drug combinations in a single assay, simplifies sample 
handling, and avoids the need to sterilize and wash dedicated microfluidic components between 
runs. 
Figure 8. Schematic of HSLCI multi-well biomass accumulation assay. A) The HSLCI system is 
configured with (i) a wide-field phase-detection camera, (ii) fiber-coupled light-emitting 
diode (LED) illumination source, and (iii) and fluorescence imaging capability (camera, filters, 
and illuminator). Motorized stages (iv) control x–y motion of the sample above the 
microscope objective, while focus is automatically adjusted continuously by a piezo actuator 
coupled to the objective [10× Nikon Plan Fluorite, numerical aperture (NA) 0.3]. B) Prior to 
imaging, cells and medium, including drug or vehicle, are dispensed into standard-format, 
glass-bottom mult-iwell plates. C) During imaging, the sample plate is translated along each 
row of wells, collecting 30 images/well on each pass. Typical imaging time is 2 min/row of six 
wells. D) Following collection, phase images are automatically analyzed in a custom pipeline 
that includes background flattening, cell detection and segmentation, and biomass 
calculation. E) Individual cells are observed between images on the basis of their position, 
and biomass versus time plots are generated. Shown is a typical normalized mass vs time 
plot for single Vemurafenib-sensitive (red) and Vemurafenib-resistant (blue) cells. 
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3.2 Methods 
Cell Lines 
M229P, M229R5, M238P, M238R1, M249P and M249R4 cell lines were grown in DMEM high 
glucose with 10% heat-inactivated FBS (Omega Scientific) and 2mM glutamine in a 37 ⁰C, 
humidified, 5% CO2 incubator. M229R5, M238R1 and M249R4 cells were exposed to 1 µM 
Vemurafenib every 2 – 3 days. Cell counting from 6-well plates with controls and a range of 
Vemurafenib concentrations was performed for five days following overnight seeding. 
Population Kinetic Response Experiments 
Cells were synchronized by growing to confluence in 75mL tissue culture flasks and collected 
using a “shake-off” technique that involved repeated tapping of the flasks against the palm to 
loosen partially-adherent (i.e. dividing) cells.  Cells were plated at 1 x 105 cells/ml in 25 mm 
dishes and incubated overnight.  Prior to imaging, samples were equilibrated thermally for one 
hour on the microscope stage, then imaged for three hours, after which either 0.1% DMSO 
vehicle control or 5 μM Vemurafenib was administered and dishes imaged for another 25 – 30 
hours.  
Vemurafenib dose response experiments.  Cells were first synchronized by shake-off, and each of 
the six melanoma cell lines seeded into four wells each of a 24-well glass bottom plate at 1 x 105 
cells/ml, and incubated overnight.  Each line was dosed with 0.1% DMSO carrier control, or 1 
μM, 5 µM, or 10 µM Vemurafenib.  Cells were incubated for 24 hours, then the entire plate was 
imaged on the HSLCI for 10 hours.   
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Fluorescence Mixing Experiments 
1.25 x 104 M249P and M249R4-GFP cells were added together in a total volume of 1mL tissue 
culture media. 0.7 mL of the mixture was dispensed into each well of an Ibidi 4-well Ph+ µ-slide. 
Cells settled over 6 hours after which 5µM Vemurafenib was added to each well. Ibidi oil sealed 
the liquid opening of each well before the plate was placed onto the LCI stage. All wells were 
imaged continuously for 48 hours. Fluorescence images were taken using a Hamamatsu EM CCD 
camera (C9100-02 EMCCD) serially after every 5 phase imaging loops were completed. Green 
fluorescence was captured using a 38 HE Green Fluorescent filter set (Zeiss) with an excitation 
wavelength of 450-490 nm, a beam splitter wavelength of 496nm and an emission wavelength of 
500-550 nm. Fluorescence excitation was provided by an X-Cite® 120Q wide-field fluorescence 
microscope excitation light source (Excelitas). 
Kinase Inhibitor Panel Assay 
M249R4 cells were plated in a 24-well optical glass-bottomed plate (Cat.# P24-0-N, Cellvis) at 1 x 
104 cells/ml (total of 1 mL in each of 24 wells) in media (DMEM, 10% Fetal Bovine Serum, 2 mM 
L-Glutamine) containing 1uM Vemurafenib. Plated cells were allowed to adhere overnight at 37 
⁰C, 5% CO2. All cells were washed with 1x phosphate-buffered saline, pH 7.4, and provided with 
fresh media. Immediately following washing and feeding, cells were dosed with inhibitors at 
dose-escalating concentrations and incubated under standard cell culture conditions for 24 
hours. After incubation, cells were imaged for 10 hours using the HSCLI system. 
3.3 Results 
Isogenic BRAFi-Sensitive and –Resistant Melanoma Cell Lines 
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We evaluated three patient-derived V600EBRAF melanoma cell lines, M229P, M238P, and 
M249P, which are sensitive to the BRAFi, Vemurafenib (IC50 < 1 μM), and their isogenic, BRAFi-
resistant sub-lines, M229R5, M238R1, and M249R4, created by Vemurafenib co-incubation over 
time (Supplementary Table 1).  M229R5 and M238R1 developed BRAFi resistance via epigenomic 
reprogramming, which is thought to occur in regressing or residual melanoma tumors from 
patients treated with MAPK inhibitor (MAPKi) therapy. This non-genomic evolution results in a 
MAPK-redundant form of resistance.33 On the other hand, M249R4 acquired a Q61KNRAS 
mutation in addition to the V600EBRAF mutation. This concurrent BRAF/NRAS mutant 
configuration results in MAPK hyper-activation and a MAPK-addicted form of resistance, which is 
frequently detected during disease progression or with clinical relapses.34-36 Thus, these pairs 
of cell lines represent pre- and post-treatment models of differential drug-sensitivity states that 
are clinically relevant and, therefore, we used these lines to evaluate HSLCI performance in 
biomass profiling.  
Biomass Kinetic Responses to Vemurafenib Exposure 
Our previous work in breast cancer and multiple myeloma indicated that changes in the 
population median growth rates between sensitive and resistant cell lines is detectable with 
confidence within a few hours of drug exposure.25,78 We also showed that the distribution of 
growth rates within a population is roughly Gaussian, in both treated and control samples.   
There is no existing data for the rate of biomass change of BRAFi-sensitive or -resistant 
melanoma cells that grow as adherent single-cells or clumps.  Therefore, we measured the 
kinetics of Vemurafenib response in the three paired, molecularly characterized melanoma lines 
using HSLCI, to establish rates and distributions of biomass change with or without drug 
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exposure. First, we performed a standard multi-day dose-escalation cell-counting assay to 
confirm sensitivity for the three parent and matched resistant lines at 1.0 µM to 10.0 µM 
Vemurafenib exposure (Supplementary Figure 2). As anticipated, the parental lines slowed and 
the matched resistant lines continued replicating with drug exposure. We next used 5µM 
Vemurafenib as the mid-point drug dose to measure the median population growth rate and cell 
mass  by HSLCI for the six cell lines in the first 25 hours of drug exposure, in order to quantify the 
average population kinetic response (Figure 9-A).  Under these conditions, drug sensitivity of the 
M249P population was detectable as early as six hours, while sensitivity of the M238P and 
M229P populations was detected at approximately 15 hours.  Significant growth rate reduction 
occurred in all three parental lines by 20 hours.  We observed significant natural variation in the 
growth rates of individual cells within each population, a result consistent with previous LCI 
studies.  The distribution of single cell hourly growth rates was typically symmetrical about the 
mean, with variation of roughly +/- 1% (SD) above and below the population mean.  For example, 
plotting the M249P growth rate distribution obtained by HSLCI for each hour showed no change 
in the population median growth rate nor in the cellular growth rate distribution over the course 
of the 25 hour experiment. (Supplementary Figure 3-A)   In contrast, under the same conditions 5 
µM Vemurafenib exposure showed population growth rate heterogeneity and a decline below 
zero growth rate by about 15 hours for >50% of cells (Supplementary Figure 3-B), indicative of 
the relative sensitivity of this line to the BRAF inhibitor.  Similar temporal single cell growth rate 
distributions were seen in the other five cell lines, with kinetics proportional to the line’s overall 
median sensitivity.  These results reproduced at both experimental sites with independently 
assembled HSLCI platforms.  
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By comparing the median cell mass of the Vemurafenib-resistant melanoma lines to the mass of 
their isogeneic, drug sensitive parent lines, we found no consistent correlation between mass 
Figure 9. Biomass accumulation response to Vemurafenib treatment. A) Normalized 
population median biomass versus time plots of each melanoma line exposed to either 5 
μM Vemurafenib (red trace) or 0.1% dimethyl sulfoxide (DMSO, blue trace). Cells were 
synchronized prior to plating in glass-bottom dishes. Each sample was imaged for 3 h, after 
which either 0.1% DMSO (vehicle control) or 5 μM Vemurafenib (treatment) was 
administered. After dosing, plates were imaged for 20–25 h by HSLCI under standard cell-
culture conditions. Typical time between repeated measurements of the same location was 
10–15 min. Each graph contains pooled data from four replicates. Error bars are ± standard 
error of measurement (SEM). B) All six synchronized cell lines were plated into a single 24-
well glass-bottom plate and dosed with either 0.1% DMSO or 1, 5, or 10 μM Vemurafenib. 
After 24 h of incubation, the plate was imaged continuously for 10 h by HSLCI. Hourly 
growth rates were automatically calculated for individual cells in each sample by linear fit to 
the biomass versus time data. Data are from a single representative experiment (n = 3). Box-
plot notches are 95% confidence intervals for the indicated medians. Each dot overlaid on a 
box plot represents the hourly growth rate of an individual cell. C) Corresponding receiver 
operator characteristic (ROC) curves for data shown in panel b. 
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and resistance (Figure 10).  This observation stands in contrast to a recent report of cell mass-
drug resistance correlation in a mouse AML model, as measured by microfluidic devices.123 
However, that study did not compare isogenic, paired sensitive and resistant tumor lines, and it 
remains to be determined whether or not mass itself is a useful metric of drug sensitivity. 
 
The mid-point kinetic response data suggested that Vemurafenib sensitivity, or lack thereof, 
would be distinguishable for all lines in a drug-escalation assay, as would be expected for cell 
counting, by measuring changes in sample growth rates after 24 hours of drug exposure.  To test 
this hypothesis, and to examine the HSLCI methodology for multi-dose and multi-agent 
screening, we collected short-term, 10-hour growth rate measurements of all three cell line pairs 
in parallel, at escalating Vemurafenib doses, using a 24-well format.  All six melanoma cell lines 
were dosed with 0.1% DMSO, or 1 μM, 5 uM, or 10 μM Vemurafenib.  The parental lines 
(M229P, M238P, and M249P) showed a clear pattern of increasing growth inhibition at 
Figure 10.  Comparing relative mass between Vemurafenib-sensitive and -resistant isogenic 
lines.  Boxplots showing distribution of single cell masses measured for each cell line.  Boxplot 
notches are indicative of the 95% confidence intervals for the medians.   
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escalating drug concentrations, whereas the resistant lines (M229R5, M238R1, and M249R4) 
showed no growth inhibition over the drug dosing range compared to a vehicle DMSO control, 
consistent with cell counting assays (Figure 9-B).   
Heterogeneity Quantification 
We used Receiver Operator Characteristic (ROC) analysis to determine the ability to distinguish 
individual resistant cells from sensitive cells, in an in silico mixture, by changes in their individual 
growth rates during exposure to Vemurafenib. (Figure 9-C)  This analysis indicated that cells from 
both M229P and M238P lines were distinguishable from their resistant derivative counterparts 
at Vemurafenib doses of 5uM (area under the curve (AUC), 0.60 and 0.85, respectively) and 
10uM (AUC, 0.78 and 0.75, respectively).  The M249P cells were the most sensitive to drug and 
easily distinguishable based on changes in growth rate, with AUC greater than 0.90 at 
Vemurafenib doses of 1uM and above (Figure 11). 
We then deployed HSLCI to quantify the changes in growth rates of an actual mixed population 
of GFP-labeled M249R4 Vemurafenib-resistant (M249R4-GFP) and unlabeled M249P 
Vemurafenib-sensitive cells during drug exposure.  Importantly, stable GFP-expression in the 
M249R4 line did not significantly alter the growth rate distribution obtained by LCI for each hour 
of 5µM Vemurafenib exposure compared with unlabeled M249R4 cells (Supplementary Figure 3-
C). Sensitive M249P and resistant M249R4-GFP cells grown together at a 1:1 ratio with 5uM 
Vemurafenib were imaged over 48 hours (Figure 12 A-C).  
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In mixed culture, individual resistant cells were discriminated from sensitive cells based on 
differences in growth rates (Figure 12-D) and because the M249R4 cells were GFP marked, they 
were easily identified relative to the unmarked M249P cells during the assay. Reproducibly, the 
population growth rate of the M249R4 cells exceeded the population growth rate of the M249P 
cells, as expected, but each marked and unmarked population also showed outlier cells. A small 
percentage of M249R4-GFP cells showed zero to slightly negative growth rates, whereas a small 
percentage of M249P cells showed net-positive growth rates, revealing unanticipated 
Vemurafenib sensitive or resistant outliers within each bulk population. As predicted from the in 
silico analysis, ROC analysis confirmed a high level of discrimination between sensitive and 
resistant melanoma cells (AUC 0.88), even when sensitive and resistant cells were combined in  
Figure 11. Vemurafenib (5 uM) sensitivity as determined by plotting pre- and post-treatment 
growth rates for Vemurafenib-sensitive (M249P) and Vemurafenib-resistant (M249R4) cell 
lines. a) Plot of pre- and post-treatment  hourly growth rates. Blue data points represent 
individual cell growth rates from the drug-sensitive cell line; red indicates data points from 
the drug-resistant line. b) ROC curve demonstrating efficacy of using calculated final growth 
rates to determine Vemurafenib sensitivity 
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the same sample wells (Figure 12-E). Similar trends were seen in 10:1 sensitive: resistant 
mixtures as well (Supplementary Figure 4). 
Figure 12. Detecting resistant cells in a mixed population. A) Optical thickness (LCI, left) and 
in-register fluorescence images (FL, right) of M249R4-GFP vemurafenib-resistant cells. B) 
LCI and fluorescence images of M249P vemurafenib-sensitive cells. C) LCI and fluorescence 
images of a 1:1 mixture of M249P (red arrows, unlabeled) and M249R4 (labeled) cells. D) 
Plot of biomass versus growth rate of a 1:1 M249P (blue)/M249R4-GFP (red) cell mixture 
exposed to 5 μM vemurafenib for 48 h. Cell identities are marked by fluorescence signals. 
E) ROC curve classifying single sensitive versus resistant cells by their growth rates during 
exposure to 5 μM vemurafenib. The blue line is calculated from M229P and M249R4 cells 
imaged in separate wells, whereas the red line is calculated from a 1:1 cell mixture in the 
same wells (representative data are shown in panel d). Data shown are from a single 
representative experiment (n = 3–5). 
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MEK Inhibitors with Vemurafenib-Resistant Melanoma 
We performed rapid HSLCI dose response assays in triplicate using a panel of three FDA-
approved and two investigational kinase inhibitors tested in clinical trials for treating metastatic 
melanoma, to simulate selection of salvage therapy for patients who develop resistance to front 
line Vemurafenib. One inhibitor in the panel targets BRAF, whereas the other four target MEK1 
or MEK1/2 (Supplementary Table 2). We selected M249R4 cells for study because of its robust 
growth profile and strong resistance to Vemurafenib.   Figure 13 shows typical results from two 
individual experimental runs, while Figure 14 shows results from all repeats fitted to a sigmoid 
dose response function, for reference.  Control DMSO-treated cells exhibited a median growth 
rate of ~2.5% per hour at 0.1% DMSO concentration (v/v), decreasing slightly to 2% per hour at 
higher concentrations (0.3%-0.5% v/v).  For each targeted kinase inhibitor, the peak tolerated 
serum concentration (Cmax (ng/mL)), as measured in clinical trials, is shown on the dose-response 
curves by an asterisk (*).  See Supplementary Methods for Cmax determination detail.  As 
expected for this highly Vemurafenib-resistant line, the BRAFi Dabrafenib showed no growth 
inhibition as compared to the DMSO control.   The MEK1 inhibitor Cobimetinib and the MEK1/2 
inhibitor Trametinib were the most effective growth inhibitors: Cobimetinib completely arrested 
median sample growth at 0.255 μM concentration, which is roughly one half of the maximum 
tolerated serum concentration, while Trametinib arrested growth at a concentration between 4 
nM and 40 nM, or between 1/10x and 1x Cmax.   MEK1/2 inhibitor Selumetinib arrested growth at 
2.55 μM, equal to 1x Cmax, while MEK1 inhibitor Binimetinib failed to halt growth at 
concentrations below 2.91 μM, or 5x Cmax, suggesting that Binimetinib would be an unlikely 
candidate for salvage therapy in this simulated case. 
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Figure 13. Effects of kinase inhibitors on Vemurafenib-resistant melanoma as measured by 
HSLCI. M249R4 cells were plated into 24-well plates and dosed at increasing concentrations 
of each inhibitor. After 24 h of incubation, the plate was imaged by HSLCI continuously for 
10 h. Typically, four different doses for each inhibitor, and four DMSO controls, were 
measured in each run simultaneously. Data in the figure represent two typical experimental 
runs, using different dose gradations. Hourly growth rates were automatically calculated for 
individual cells in each sample by linear fit to the biomass vs time data. Each box plot 
summarizes the hourly growth rates of a population of cells exposed to escalating 
concentrations of each drug. Individual dots in the underlying scatter plots represent the 
growth rates of single cells. Boxplot notches are indicative of 95% confidence intervals for 
the medians. Median number of cells per well: top panel 159 (range 79–216); bottom panel 
160 (range 59–294). 
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Figure 14. Summary of effect of five kinase inhibitors on Vemurafenib-resistant melanoma as 
measured by HSLCI.   M249R4 cells were plated into 24-well plates and dosed at increasing 
concentrations of each inhibitor.  After 24 hours incubation, plates were imaged by HSLCI 
continuously for 10 hours. Hourly growth rates were automatically calculated for individual 
cells in each sample by a linear fit to the biomass versus time data. Data for each drug-dose 
combination shown represents a sum of three independent replicates. Each boxplot 
summarizes the hourly growth rates of a population of cells exposed to escalating 
concentrations of each drug. Individual dots in the underlying scatter plots represent the 
growth rates of single cells. Boxplot notches are indicative of the 95% confidence intervals for 
the medians. Median population growth rates from all kinase panel repeats are plotted and 
fitted with sigmoid curves. Error bars indicate the 95% confidence intervals for the medians.  
The doses indicated by an asterisk (*) correspond to the maximum serum concentrations 
(Cmax) measured in the blood during clinical trials at FDA-approved therapeutic doses. Median 
number of cells tracked per well per replicate was 159 (range 79 - 294). 
 
41 
 
3.4 Discussion 
Here, we demonstrated the ability of our rapid HSLCI platform to quantify individual cell drug 
sensitivity in tumor cell populations. This quantification may provide critical data for treatment 
selections on a whole-tumor population level and can identify specific subpopulation drug 
sensitivities to predict drug resistance at a single cell level. Our results also show the 
reproducibility of two similar but distinct implementations by obtaining concordant data from 
two institutions with independently constructed and standardized HSLCI platforms. This two-
center study design is unique amongst live cell response profiling approaches and provides 
confidence that the newly configured HSLCI has the required consistency for further 
development towards a clinically useful approach.  
In comparison to other single live cell biomass profiling approaches, including our own prior 
interference microscopy studies, HSLCI represents a substantial technical advance in single cell 
sampling throughput, cell tracking duration and parallel measurement of multiple 
agents.34,36,74,78  For example, Stevens et al. recently used micro-channel resonators to 
demonstrate that the combined measurement of single cell mass and growth rates could be 
used to identify drug resistant cells isolated from an engineered mouse AML model.28   Their high 
throughput ‘next-gen’ system with 12 micro-resonators could measure up to 60 cells per hour,  
where cells are measured serially, each for 15 minutes, resulting in simple ‘snapshots’ in time. 
Unfortunately, tumors that grow in small clusters or clumps, as do many melanoma samples, are 
inaccessible to this platform unless they are disaggregated, which affects their growth 
characteristics and drug sensitivity.    In contrast, HSLCI typically measures between 103 and 104 
cells in each experiment, tracking each cell individually for hours to days, and is well suited to 
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tumors that grow in clusters or clumps without disaggregation.  In addition, identifying rare 
resistant clones in a population of normal or therapy-sensitive malignant cells will require deep 
sampling.  For instance, typical minimal residual disease detection using multi-color flow 
cytometry requires sampling to a depth of at least 104 and up to 106 cells.124   We believe that 
realistic improvements may allow HSLCI throughput to approach 105 cells per experiment. 
Due to the mechanical and environmental stability of the HSLCI system, we have been able to 
track single cells and cell clusters for up to 10 days, with no time limit yet found.  This is a 
dramatic increase over our previous 12-hour maximum duration interference microscopy work, 
and enables studying behaviors that evolve over many minutes, hours or days, encompassing the 
vast majority of cellular responses.   Cell tracking duration is of direct relevance to detecting drug 
responses in cells isolated from patients, as it is necessary to distinguish between growth-arrest 
(cytostasis) and death resulting from drug exposure versus other influences.   With HSLCI this is 
accomplished by repeatedly observing individual cells before and after drug exposure-response, 
a process that requires several hours or more. 
The primary drawback of HSLCI compared to microscopic, single cell ‘snapshot’ fluorescent 
assays and micro-resonator mass assays is the relatively large data footprint and extensive image 
analysis required to generate a biologically interpretable result.  At present, data analysis time, 
not hardware capability, is throughput limiting.  On the other hand, the single cell images 
generated by HSLCI are inherently information rich, allowing not only mass accumulation but 
cytokinesis, motility and cell shape information to be quantitated.   Integrating these mutually 
supporting metrics will be a direction for future research.   Furthermore, system upgrades can be 
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largely accomplished by software rather than hardware modifications, making the upgrade path 
efficient and flexible. 
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Chapter 4 
CD3+ T Cell Mass Dynamics During Stem Cell Transplantation 
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4.0 Chapter Overview 
This chapter details the use of LCI to analyze T cells extracted from the blood of patients 
undergoing stem cell transplantation at VCU’s Massey Cancer Center. This project was planned 
and executed in close collaboration with Dr. Amir Toor and Dr. Catherine Roberts. The text and 
figures that follow have been adapted (reproduced with permission of The Royal Society of 
Chemistry and co-authors) from a publication of the study’s results, first-authored by K. Leslie, in 
the journal Analyst.125,126  
4.1 Introduction 
Approximately 32,000 allogeneic stem cell transplants (SCTs) from HLA-matched donors are 
performed annually.127 In addition to an increased susceptibility to infection, recipients of these 
transplants face competing risks of malignancy relapse and graft versus host disease (GVHD). In 
HLA-matched SCT recipients, GVHD results from the recognition of recipient minor 
histocompatibility antigens by donor T cells. Despite an evolving understanding of the 
complexities of these alloreactive T cell responses and significant reductions in non-relapse 
mortality (NRM), the incidence of GVHD ranges from approximately 10% to 50% for allogeneic 
SCT recipients.128 This is particularly problematic as an increasing number of SCTs are performed 
each year, matched unrelated donors are utilized in more than half of allogeneic transplants, and 
increasingly older patients now undergo transplantation using reduced-intensity conditioning 
where a graft versus tumor (GVT) effect is critical for disease control and GVHD is especially 
deleterious. Furthermore, no reliable laboratory measures have yet emerged to allow real-time 
titration of post-transplant immunosuppression on an individualized basis to modulate 
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competing GVHD and cancer relapse risks. Essential to the development of such measures is an 
improved understanding of the immunobiological mechanisms underlying discrepancies in GVHD 
incidence, such as further characterization of the biological diversity of transplant donors and 
recipients, and efforts to identify a comprehensive marker of post-transplant alloreactivity.129,130 
Given the central role of T cell growth and differentiation in SCT, and that of processes known to 
alter cellular size and shape, one approach to studying alloreactivity in real-time might involve an 
assessment of donor-derived T cell biophysical properties. It has been shown in vitro that CD8+ 
murine T cells increase their mass upon activation and, further, that cytotoxic T cells transiently 
increase their mass when effecting cell killing, in a stylized cell culture system.58,131 Mathematical 
modeling by Toor et al. has identified distinct population growth kinetic signatures of 
lymphocyte recovery that correlate with levels of donor-derived CD3 + T cells and 
alloreactivity.132,133 Further, it has been shown that there are significant metabolic adaptations in 
T cell subsets upon engagement of an antigenic peptide-HLA complex by the T cell receptor. 
These metabolic changes include increased glycolysis and oxygen consumption as well as 
cytokine production.134 Higher levels of GLUT 1 expression have been observed in activated T 
cells, again suggesting increased metabolic & biosynthetic rates.135 Indeed, a weak correlation 
has been shown between intracellular ATP concentration in T cell subsets and severity of clinical 
GVHD in humans and between increasing glycolysis and GVHD in murine models.136,137 These 
results suggest that T cell activation and consequent metabolic, biosynthetic, and, logically, mass 
changes, may correlate with significant functional events in the SCT immune reconstitution 
process, as donor-derived T cells experience a new antigenic milieu, post-transplant. 
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At the time of this study, the HSLCI was still under development. Therefore, using the lower-
throughput LCI system, we measured biomass in populations of CD3 + T cells isolated from 
hematopoietic stem cell transplant patients, at various times pre and post-transplant, with an 
aim to identify kinetic signatures associated with immune reconstitution and GVHD.  
4.2 Methods 
Consecutive patients undergoing myeloablative conditioning and stem cell transplantation 
between May 2015 and May 2016 were enrolled on a prospective study approved by Virginia 
Commonwealth University's Institutional Review Board (VCU-IRB #HM20004916) (Table 1). 
Patients gave informed consent for stem cell apheresis product and whole blood sample 
collection, and for rabbit anti-thymocyte globulin (Thymoglobulin) either 3.5 mg kg−1 (MRD) or 5 
mg kg−1 (MUD) starting from day-3 to day-1. GVHD prophylaxis was with either tacrolimus or 
cyclosporine in combination with methotrexate (MTX) or mycophenolate mofetil (MMF). 
Antimicrobial and antifungal prophylaxis was administered. Routine surveillance for 
cytomegalovirus (CMV) and Epstein Barr virus (EBV) was carried out using PCR. Donor cell 
chimerism was studied using short tandem repeat sequence PCR. Average T cell chimerism for 
allogeneic transplant recipients was 90% at 30 days post-transplant (T30), 99% at 60 days post-
transplant (T60), and 99% at 90 days post-transplant (T90). Donor-derived CD3 + T cell (ddCD3) 
counts were calculated as previously reported.130 Average ddCD3 cell counts were 571 cells per 
μl, 1417 cells per μl, and 1019 cells per μl at 30, 60, and 90 days post-transplant, respectively. 
48 
 
Patients have had a median follow up 
of 11 months (range: 0.27–15.7) 
following SCT. Of the patients that 
underwent allogeneic SCT, 9 (69%) 
developed either acute or chronic 
GVHD. Median onset of acute GVHD (n 
= 7, 6 MUD recipients) and chronic 
GVHD (n = 4, all MUD recipients) were 
at 58 and 126 days post-transplant, 
respectively. The incidence of grade 
3–4 acute GVHD was 15% and the 
incidence of moderate to severe 
chronic GVHD was 23%. Relapse 
occurred in one MUD recipient and 
CMV/EBV reactivation developed in 
nine and five (6/3, 4/1 MUD/MRD) 
patients, respectively. Seven of eleven 
MUD recipients are surviving, as are all 
MRD and autologous SCT recipients. 
Post-transplant, two patients 
diagnosed with GVHD later died; after 
n=18
Median Age, y (range) 49 (24-65)
Gender
  Female 9
  Male 9
Disease
  Acute lymphoblastic leukemia 3
  Hodgkin's lymphoma 2
  Myelodysplastic syndromes 4
  Chronic myelogenous leukemia 1
  Non-Hodgkin's lymphoma 3
  Acute myeloid leukemia 2
  Multiple myeloma 1
  Myelofibrosis 2
Donor Type
  Matched unrelated 11
  Matched related 3
  Autologous 4
Conditioning Regimen
  TBI/Cyclophosphamide 2
  Busulfan/Cyclophosphamide 6
  Busulfan/Fludarabine 4
  Fludarabine/Melphalan 2
  BEAM 3
  Melphalan 1
CMV Status (Donor/Recipient)
  +/+ 7
  +/- 3
  -/+ 4
  -/- 0
GVHD Prophylaxis
  Tacrolimus-Methotrexate 6
  Tacrolimus-Mycophenolate mofetil 4
  Cyclosporin A-Methotrexate 2
  Cyclosporin A-Mycophenolate mofetil 1
Median CD34 Dose (E6 cells/kg) (range) 4.59 (3.11-9.40)
*Scheduling and dosing for conditioning regimens w ere as follow s:
•TBI/Cy 2 Gy TBI in 6 fractions bid days -6, -5, -4; Cyclophosphamide 60mg/kg/day days -3, -2
•Bu/Cy  Busulfan 0.8 mg/kg for 16 doses days -7, -6, -5, -4, -3; Cyclophosphamide 60 mg/kg/day days -3, -2 
•Bu/Flu Fludarabine 40 mg/m2 days -5, -4, -3, -2; Busulfan 130 mg/m2 days -4, -3, -2
•Flu/Mel Fludarabine 30 mg/m2 days -6, -5, -4, -3; Melphalan 140 mg/m2 day -2
•BEAM Carmustine 300 mg/m2 day -7; ara-C 100 mg/m2) for 8 doses days -6, -5, -4, -3; Etoposide 100mg/m2 
          for 8 doses days -6, -5, -4, -3; Melphalan 140 mg/m2 day -2
•Melphalan 200mg/m2 day -2
Table 1. Patient demographics 
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suffering multiple infections, one patient that remained GVHD-free died. 
Cell Mass Measurements 
Donor samples were obtained for mass measurement from apheresis products, with a 2 mL 
aliquot provided for each patient. Transplant recipient whole-blood samples (3 mL) were drawn 
at 14 ± 3, 28 ± 3, 56 ± 3, and 100 ± 3 days post-transplant. After acquisition, whole-blood 
samples were stored at +4 °C for no longer than four hours prior to cell isolation. CD3 + T cells 
were isolated directly from donor products and patient whole blood samples using the 
Dynabeads FlowComp Human CD3 Kit (ThermoFisher). Isolated cells were resuspended in 500 μl 
sterile phosphate-buffered saline.  
For mass imaging, isolated CD3 + cells were transferred to optical glass-bottomed cell culture 
dishes to a maximum concentration of 1 × 106 cells per mL in a 3 mL volume of sterile PBS (Figure 
15-A).  
Figure 15. Sample 
preparation and analysis 
procedure.  
A) Immunomagnetic beads 
were used to isolate CD3 + T 
cells from patient whole 
blood or donor apheresis 
product samples. B) 
Histogram of CD3 + T 
biomass distribution from a 
representative sample. C) 
Typical quantitative phase 
image of CD3 + T cells. 
Height and coloration are 
proportional to optical 
thickness. 
50 
 
Measurements were taken using a 40X objective (Nikon, NA 0.75) under standard cell culture 
conditions (37 °C, 5% CO2). The mass of each cell was calculated by taking the median of 20 
individual mass measurements. Figure 15-B shows a representative histogram of single T cell 
masses found in a patient. The mass distribution was roughly symmetrical, with most median 
masses between 60–80 pg, and intra-patient variation of roughly 30 pg. Figure 15-C shows a 
typical field of view rendered as a 3D image, with height corresponding to local mass density or 
‘optical thickness’. Individual cells appeared as extended spheres of varying density, therefore 
cellular diameter alone was not a good predictor of overall mass. 
4.3 Results 
T cell mass population medians for each sample are presented in Figure 16 as a function of time 
post-transplant. We found a pronounced rise in median T cell biomass vs. infused product 
(median +25%; p < 0.001; Student's t-test) shortly after transplant (day 14), which moderated by 
day 60. Further, the inter-patient and intra-patient cell masses were most variable at days 14 
and 30 post-transplant in both allogeneic and autologous SCT recipients (data not shown), when 
the ddCD3 count was the lowest. This is certainly consistent with the notion of a larger 
proportion of T cells post allograft being activated due to the inflammatory milieu resulting from 
conditioning related tissue/endothelial injury, infections and, in allogeneic transplant recipients, 
GVHD developing post-transplant.138,139 
Our group has previously reported that lymphocyte count and CD3 + cell recovery post-
transplant occurs as a logistic function of time, with exponential expansion occurring in the first 
few weeks following transplantation.133 The observation that T cell mass is high at these early 
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time points is consistent with the notion that higher mass may be observed in proliferating T 
cells. The initial peak and then later plateau effect seen in our T cell mass observations is also 
reflected in T cell growth kinetics recorded following viral infections, which again has to do with 
antigen-driven 
 
 proliferation.140 An alternative interpretation is that this high T cell mass in the first days reflects 
the effect of a ‘cytokine storm’ following SCT.141 Further, the lympho-depleted milieu of the early 
Figure 16. Biomass of patient-derived CD3+ T cells post-transplant. Median CD3+ T cell 
masses for all patients, grouped by time of sample acquisition (days post-transplant). Each 
point represents a single patient per time point; autologous transplant patients (green 
squares), allogeneic transplant patients (circles).  For the allogenic transplants, white 
circles indicate an absence of GVHD during the course of the study, while black circles 
indicate a diagnosis of GVHD.  Solid black lines indicate the average T cell mass for all 
patients at the specified time point. Bars above and below the data points indicate 
significant median cell mass differences between all patients at two different time points 
as calculated by Student t-tests. 
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post-transplant period may also contribute to the rapid growth of T cells and mass acquisition. In 
future studies, as T cell mass is measured, markers of proliferation will have to be assessed 
simultaneously to discern the effect of proliferation vs. T cell activation. Patients who developed 
GVHD tended to have persistently elevated or increasing masses at days 60 and 100 compared 
with their infused product T cell mass. Patients with GVHD exhibited a 
 
significant (p = 0.006; Student's t-test) difference between product and day 100 normalized 
median masses, showing a persistent elevation (∼18% higher median T cell masses than infused 
stem cell product) beyond day 30. Five patients exhibited a 20% or greater increase in median T 
cell mass at day 60 or 100, two of whom developed grade III–IV acute GVHD and one, severe 
Figure 17. Biomass and GVHD grade 
of patient-derived CD3+ T cells 60 
and 100 days, post-transplant. 
Median masses by GVHD status and 
transplant type, normalized to the 
mass of the T cells infused into the 
patient.  Each data point represents 
the median CD3+ T cell mass for one 
patient at a specified time point. 
Roman numerals indicate maximum 
acute GVHD grade, if present. 
Maximum severity of chronic GVHD 
is expressed as either mild, 
moderate, or severe, if present. 
Points with a contrasting center 
indicate patient is now deceased.    
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chronic GVHD (Figure 17). A representative example of one of these five patients is contrasted 
with a patient who did not develop GVHD, in Figure 18.  
 
Finally, one of our patients, a 24-year-old male with Hodgkin's Lymphoma, suffered Grade III 
aGVHD and exhibited normalized median T cell masses of 32% (day 60) and 25% (day 100) 
greater than the infused stem cell product. The initial cell mass increase was coincident with 
Epstein Barr virus and Cytomegalovirus reactivation. Another, a 65-year-old male with 
Myelodysplastic Syndrome, was diagnosed with severe cGVHD and exhibited median T cell 
Figure 18. Boxplots showing normalized T cell population mass distributions, over time, for 
two representative allogeneic transplant recipients.  Product, Day 30, Day 60, and Day 100 
mass measurements were normalized to the median mass of the patients’ product 
samples. All individual cell masses (blue dots) measured at a given time point have been 
overlaid onto that time point’s boxplot. A) Patient did  not develop clinical signs of GVHD 
during the course of the study. Median CD3+ T cell mass increased at day 30, but 
decreased and stabilized through days 60 and 100. B) Patient developed severe chronic 
GVHD involving the lungs 151 days post-transplant. Median CD3+ T cell mass increased 
44% above the product sample median at day 30, and remained elevated through day 100. 
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masses 36% and 45% greater than infused stem cell product cells at days 60 and 100, 
respectively. Both patients later died.  
4.4 Discussion  
If this observation is validated in a larger cohort, T cell biomass could become invaluable as an 
inexpensive biomarker of alloreactivity and GVHD risk, and be used to guide decision making 
about intensity of immunosuppression post-transplant. This may also be a useful adjunct to PCR-
based diagnosis of viral reactivation, where low level reactivation often raises the conundrum of 
whether toxic therapy should be initiated or held off on. Patients with high mass T cells in these 
instances may indeed be in the process of mounting a protective response and may be followed 
without introduction of cytotoxic drug therapy. Increasing the post-transplant sampling 
frequency would also be beneficial in order to account for the variability in onset of GVHD 
symptoms and better mitigate the effects of infections, viral reactivation, and relapse on T cell 
mass. Importantly, continued development of GVHD predictive models using T cell mass-based 
methodology must account for such potential confounding effects on this measure. However, 
contextualizing T cell mass measurements with conventional clinical manifestation of infections 
and GVHD, as well as with biomarkers, may allow real time titration of immunosuppressive 
therapy.142 
In order to simultaneously develop a more precise view of post-transplant alloreactivity and 
elucidate underlying immunobiological mechanisms, it will be necessary to go beyond CD3 + cell 
isolation and characterize relevant T cell subsets within each sample. Based on prior work by 
Meier et al. and Berrie et al. that highlight normal reconstituting T cell diversity and identify the 
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emergence of a limited number of dominant T cell clones in patients with GVHD, simultaneously 
assessing T cell clonality and mass during immune reconstitution could enhance the specificity of 
any predictive signatures.143–146 Cell mass spectra might also complement other modalities, 
including newly vetted biomarker panels for NRM and GVHD, such as those developed by 
Hartwell et al., as well as donor-derived T cell counts, lymphocyte reconstitution kinetics, and 
predictive modeling of minor histocompatibility antigens.147 Our findings underscore the notion 
that alloreactive T cell response is a multifaceted reaction of the donor T cells to the recipient 
milieu. Aside from proliferation and T cell subset differentiation, there are critical metabolic and 
functional changes associated with antigen recognition, which may result in biomass change.148 T 
cell subsets are of crucial importance to GVHD pathophysiology, therefore, measurement of T 
cell (and T cell subset) mass is a simple, clinically applicable parameter that summarizes the 
latter two adaptations of T cells to the change in the ‘antigenic landscape’.149 Despite a small 
patient cohort, results from this study provide the foundation for the continued assessment of T 
cell population mass in understanding and predicting metabolic changes in the T cells associated 
with alloreactivity and, subsequently, providing guidance for immunosuppression titration in 
allogeneic SCT recipients. 
The cell mass measurement method we use is one of many available options, each of which has 
strengths and weaknesses depending on the application. The technical performance of the 
phase sensing camera employed has been well documented by the manufacturer in a series of 
papers.26,79,80 Our results suggest that other quantitative phase microscopy modalities, in 
particular digital holography, could be employed for this application with success.150,151 Our LCI 
system was automated for ease of use and reproducibility, but would not be considered high-
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throughput. Improving the throughput and robustness of quantitative imaging platforms is an 
important direction of research for the field. 
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Chapter 5 
Applications in Basic Research 
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5.0 Chapter Overview 
This chapter details experiments investigating apoptosis in established cancer cell lines, the 
kinetics of degranulation in mast cell populations, and cell growth patterns in genetically 
engineered Kaposi’s sarcoma cells during the latent-lytic switch of an oncogenic virus.  
5.1 Apoptosis Assays 
5.1.1 Introduction 
As previously discussed, LCI’s utility hinges on the ability to correlate biological events of interest 
with changes in the mass of the cells being observed. Experiments designed to validate these 
correlations are typically conducted using LCI in parallel with established analytical methods. 
Considering our initial goal of assessing the response of cancer cell lines to cytotoxic drugs, the 
ability to quantify cell death in terms of changes in mass was an important early milestone.  
Cell death can occur as a result of internal processes like cell aging or external factors like acute 
injury or disease and, further, can proceed via several mechanisms.152 Injury and disease typically 
cause cells to die by necrosis, while certain drugs, immune cell killing, cell aging, and mitotic 
errors result in programmed cell death via apoptosis or autophagy.153–155  
Of the cell death mechanisms, apoptosis is particularly dramatic owing to its irreversible nature 
and array of associated morphological changes.156 Commercially-available kits can detect 
different stages of apoptosis using cytotoxic chemicals and fluorescent dyes, allowing 
researchers to understand the impact of specific conditions or drugs on a given cell.157 By 
coupling LCI and fluorescent imaging, we hypothesized that the induction of apoptosis and 
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subsequent cell destruction would result in significant decreases in mass that correlated with 
appropriate fluorescent dye signals. Based on this hypothesis, we designed an experiment to 
evaluate the correlation between mass loss and fluorescently-indicated apoptosis in established 
lung (A549), kidney (786-0), and breast (MCF7) cancer cell lines. 
Briefly, cells would be exposed to the apoptosis-inducing agents Actinomycin D and 
Camptothecin in the presence of the fluorescent dyes YoPro1 (YP1) and Propidium Iodide (PI).158 
YoPro1 is a DNA-intercalating dye that fluoresces green; PI is a DNA-intercalating dye that 
fluoresces red.159,160 Both dyes enter cells through plasma membranes whose structures have 
been compromised due. Because apoptosis triggers morphological changes that compromise a 
cell’s plasma membrane, these dyes can enter and bind to DNA. Importantly, as the smaller of 
the two dyes, YP1 is capable of entering dying cells earlier than PI. Taken together, we would 
expect that cells exposed to Actinomycin D and Camptothecin, in the presence of YP1 and PI, 
would simultaneously exhibit a detectable loss of mass while first fluorescing green and then red.  
5.1.2 Results & Discussion 
Control groups in each of the three lines exhibited steady single-cell growth rates of 2%/hr (MCF-
7), 2%/hr (786-0), and 3%/hr (A549). As expected of cultured populations, ~5% of cells in each 
control group were non-viable as evidenced by detectable YP1 and PI fluorescence.   
Treatment groups for each line exhibited pre-dosing growth rates similar to controls. After 
dosing, median mass lost per cell ranged from 10-60%. Line A549 responded both more robustly 
and more quickly than the other two lines, with PI fluorescence visible in almost all cells within 
140 minutes of treatment and median mass loss per cell of approximately 40%. In line 786-0, PI 
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fluorescence was similarly visible for all cells by 200 minutes, post-treatment, with a median 
mass loss of 30%. Finally, line MCF-7 exhibited the slowest response, with PI fluorescence visible 
in all cells at approximately 450 minutes after dosing. Results are summarized in Figure 19. 
Data show a correlation between the timing of drug-induced apoptotic mass loss and PI 
fluorescence in all three lines measured. However, variation between the extent and the timing 
of mass loss between cell lines was apparent. Interestingly, the longer the published doubling 
time for each cell line, the longer the amount of time required to induce mass loss and 
fluorescence. While the underlying mechanism behind this observed disparity in timing is 
unclear, our results demonstrate a clear link between the timing of cell mass loss and the 
fluorescence of established markers following exposure to inducers of apoptosis.  
5.1.3 Methods 
For each experimental replicate, cells were seeded at 5 x 104 cells/ml in a 25 cm2 diameter 
optical-glass-bottomed dish and allowed to grow for 24 hours in appropriately-supplemented 
RPMI 1640 or DMEM-based media under standard mammalian cell culture conditions (5% CO2, 
37 ⁰C). Media was exchanged 24 hours after plating. After the media exchange, the dish was 
placed on the sample stage in the LCI system for one hour to reach thermal equilibrium. YP1 and 
PI were added to the dish to final concentrations of 1 μM and 1μg/mL, respectively. After dosing, 
brightfield, fluorescence, and phase images were collected for one hour, at 10X magnification, in 
a 3x3 grid pattern to measure baseline growth rates. After one hour, 1X concentrations of 
Actinomycin D and Camptothecin were administered, and imaging proceeded for an additional 
800 minutes. 
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Figure 19. Correlation of apoptosis, PI fluorescence, and mass loss in three cancer cell Lines. 
Established cancer lines A549 (lung), 786-0 (kidney), and MCF-7 (breast) were measured for 
400 minutes using LCI. 60 minutes after the start of imaging (vertical dotted blue lines), 
treatment group cells were dosed with Actinomycin D and Camptothecin to induce apoptosis. 
The upper panel depicts mass vs. time scatter plots of each individual cell tracked during a 
single experimental replicate. Blue lines represent the median normalized mass of all cells at 
each time point, while black lines represent the bounds of the 95% confidence interval for the 
median. The lower panel depicts total red channel fluorescence intensity (i.e. the PI signal) 
over time for each location (individual lines) imaged in a given sample. Note: the brief spikes 
in fluorescence intensity following treatment represent a temporary recovery by fluorophores 
from photo bleaching. Median number of cells measured in each replicate was 109.  
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For each cell line, one control (media vehicle) and three treatment replicates were performed.  
To ensure consistency and enable troubleshooting, the temperature and CO2 concentration in 
the incubator (as well as the Z focus position of the objective) were logged during each 
experiment. These measurements are critical because fluctuations in any of the three metrics 
can alter the mass measured by the LCI, either by actually impacting the biological health of a 
cell, or producing out-of-focus images that result in artificially high or low measurements. 
5.2 Mast Cell Biology 
5.2.1 Introduction 
Mast cells are multifaceted components of the immune system best known for their role in 
mediating allergic responses.161,162 They are found in almost all tissues of the body, including the 
skin, gastrointestinal tract, respiratory mucosa, brain, and peritoneal cavity.163  Capable of 
responding rapidly to stimuli, mast cells contain an array of effector molecules (mediators), 
including histamine, serotonin, and multiple cytokines.164–166 The majority of these mediators are 
packaged into granules and, upon a cell receiving a sufficient signal to “degranulate,” are 
released.167 Effects of mediator release are numerous, including changes in the permeability of 
blood vessels and the recruitment of immune cells.161 In addition to their role in normal 
physiological responses, mast cells are implicated in wide range of conditions and diseases, 
including cancer, cardiovascular disease, obesity, and autoimmune diseases.168–172  
Degranulation is the process by which mast cells release their array of preformed mediators. The 
process can be initiated through a variety of pathways, though the most common is IgE-
mediated.173–175 Briefly, mast cells express FcεRI, a high-affinity receptor for IgE, on their 
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surfaces. IgE binds to FcεRI receptors and, when bound by its specific antigen, results in the 
crosslinking of multiple FcεRI receptors. This crosslinking triggers a signal cascade that ultimately 
results in the release of intracellular calcium and, subsequently, degranulation.176 Once 
degranulation has been initiated, granules move to the mast cell’s membrane, fuse, and release 
their contents. This entire process occurs in minutes and is accompanied by striking 
morphological changes.177–179  
As degranulation plays a central role in mast cell activity, studying its biological underpinnings 
enables both a better understanding of mast cells’ roles in disease and our ability to develop new 
therapeutic interventions.180 Of particular relevance are characterizing the quantities of 
mediators released and the recovery period required between successive triggering events.181–
183 Literature on the latter is sparse, with one study suggesting an approximately 48-hour 
recovery period in murine bone marrow-derived mast cells.179 Research laboratories commonly 
measure degranulation by fluorescently tagging released effector molecules like histamine, 
prostaglandin D2, beta-hexosaminidase, or IL-6 and then quantifying fluorescent signals.184 This is 
a useful “endpoint assay” approach, but it precludes labeled cells from being using in 
downstream experiments and requires bulk averaging of signals from cells in a population. 
Our goal, in close collaboration with Dr. John Ryan’s laboratory in the VCU Department of 
Biology, was to evaluate LCI and HSLCI as label-free tools for studying mast cell biology. In the 
process, we hoped to gain insight into how much mass was lost by mast cells undergoing 
degranulation in response to various stimuli and how long it takes for them to recover from this 
process.   
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5.2.2 Approach 
Our approach centered around a robust characterization of mast cell population mass, size, and 
behavior. A series of population-level and single-cell experiments were conducted. Briefly, 
investigations of cell mass distributions and measurement reproducibility involved imaging 
thousands of mast cells from distinct populations to examine intra- and inter-batch variation, as 
well as differences between unprimed, primed, and triggered cells. Degranulation assays focused 
on measuring mast cell masses before, during, and after the administration of known triggering 
agents to examine response kinetics and recovery time. These assays were also conducted using 
established fluorescent markers to correlate mass loss events with cell membrane disruptions 
associated with degranulation.  Two triggering agents were used: Ionomycin, a calcium 
ionophore, and DNP-HSA, a biologically-relevant antigen. 
5.2.3 Results 
Cell Mass Distribution and Variation 
Taken together, population-level studies revealed a consistently positively skewed distribution of 
masses within a given mast cell population. Median masses ranged from 150-350 pg. The 
distribution of cell masses in a representative population is show in Figure 20. Variation in pre-
treatment median masses between different cell batches was observed, with the largest median 
masses measuring 2X larger than the lowest recorded medians. Experiments comparing the 
masses of primed vs. unprimed cells from the same batch of cells revealed median masses in 
primed cell populations to be 4-9% larger than unprimed populations. 
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HSLCI Degranulation and Recovery Assays 
HSLCI degranulation and recovery assays revealed the presence of two distinct groups of cells 
based on cell size and mass (Figure 21). These groups were present in all samples and all 
treatment groups. Interestingly, the smaller of the two groups remained essentially static 
throughout the course of each experiment, neither gaining or losing mass or area. This group 
was termed “Static.” The larger of the two, termed “Active,” exhibited growth in all experiments. 
Further, a re-analysis of data from experiments conducted on the original LCI system revealed 
the presence of these same two distinct populations of cells.  
Figure 20. Distribution 
of cell masses from a 
single mast cell 
population. Histograms 
depicting the distribution 
of mast cell masses from 
a single population, as 
measured by LCI. Cells 
from the same 
population were 
measured during two 
independent but 
identical experimental 
replicates (Repetition 1 
and Repetition 2). 
Median masses and total 
cell counts (n) are 
displayed in the top right 
corner of each plot.  
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Examples of both successful and unsuccessful DNP-HSA triggering of cells in the Active groups 
are shown in Figure 22-A. An analysis of pre-treatment population median masses revealed that 
degranulation was only detected in the two most massive mast cell populations (Figure 22-B). In 
addition, in these responsive groups, a distinct pattern emerged in which treated cells rapidly 
lost mass in response to DNP-HSA, then rapidly increased in size (area). Their size quickly 
diminished to pre-treatment levels and the growth of the cells (in terms of mass and area) 
resumed (Figure 23).  
 
Figure 21. Distinct mast cell sub-populations. A) A scatter plot of cell mass vs. cell 
diameter from a single time point (prior to treatment) during a representative HSLCI 
experiment. Each point represents a single mast cell. Coloration was applied to highlight 
the two populations (Green = “Active”, Gray = “Static”); data points are rendered semi-
transparent to enable visualization of density. B) A scatter plot of median cell mass vs. 
time for the two groups, plotted with underlying lines depicting the best linear fits.  
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Figure 22. HSLCI-measured DNP-HSA response kinetics and inter-population mass 
variation. A) Plot of median Active cell mass vs. time for three different representative 
DNP-HSA response assay replicates, as measured by HSLCI. Dotted lines represent control 
groups, while solid lines represent groups treated with DNP-HSA. Green coloration 
indicates an experiment in which degranulation was successfully detected. Blue 
coloration indicates that no degranulation was detected. Numbers and coloration 
correspond to those shown in B. B) Bar plot of pre-treatment median masses from 
independent HSLCI experimental replicates. As stated previously, coloration indicates 
whether or not degranulation was measured in response to DNP-HSA treatment. 
Experiment number is arbitrary and not reflective of chronological order. Median number 
of cells measured for each experiment was 1422. 
Figure 23. Active group mass and area versus 
time.  Representative plot of Active group 
centroids from Triggered (DNP-HSA) and 
Control BMMC populations, as measured by 
HSLCI and identified using mixed model 
fitting in MATLAB. Decreasing line 
transparency corresponds with increasing 
time. Time between successive data points is 
identical. Note the rapid loss of mass and 
increase in area, followed by recovery, in the 
treated population. 
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Correlation of Degranulation with Mass Loss and Fluorescence 
Methylcellulose was successfully employed in short-term fluorescence correlation experiments. 
Mass losses ranging from 20-50% were observed in hundreds of individual cells suspended in 1% 
methylcellulose following the administration of Ionomycin. The appearance of fluorescent signals 
from PI and YP1 correlated precisely with the decline of each cell’s mass, with YP1 (the smaller of 
the two molecules) appearing several minutes prior to PI. A single-cell example is provided in 
Figure 24. 
 
Characterization of RBL-2H3 Degranulation and Recovery 
Tumor line RBL-2H3 control and pre-treatment cells exhibited growth rates ranging from 2-5% 
per hour. Cells treated with 1X DNP-HSA exhibited a rapid 30-50% decrease in mass within one 
hour of dosing, while control cells grew unabated (Figure 25). Interestingly, mass lost by treated 
cells was recovered within 1-3 hours, with cells continuing to grow steadily at 2-3% per hour for 
18 more hours. In addition to their robust growth, many RBL-2H3 cells exhibited significant 
Figure 24. Correlation of Ionomycin 
dosing with mass loss and YoPro1 
and PI Fluorescence in a single mast 
cell. A scatter plot of cell mass vs. 
time for a single mast cell. 
Ionomycin was administered at T = 
20 minutes. Fluorescence images A, 
B, and C correspond to the time 
points labeled on the scatter plot 
indicating the appearance of green 
and then red fluorescence.  
69 
 
motility during the experiment’s 20-hour duration. This is consistent with behavior noted in 
other studies.185 
 
Figure 25. RBL-2H3 cell degranulation and recovery. Upper Panel) Cell mass versus time plot 
for two representative RBL-2H3 cells. Cells were imaged using LCI for one hour, DNP-HSA or 
media vehicle was administered, and imaging resumed for 11 more hours. The red line 
represents the DNP-HSA treated cell. The blue line represents the Control (media vehicle-
treated) cell. Lines were smoothed using an interpolated spline function (fnplt, MATLAB). 
Letters A-D and gray vertical lines correspond to selected time points for which cell images 
are provided in the lower panel. Lower Panel) Images of the triggered and control cells 
plotted in the upper panel, at time points A-D. White arrows indicate the cells whose 
measurements are plotted.  
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5.2.4 Discussion 
Taken together, the data demonstrate LCI and HSLCI’s ability to reliably detect and measure 
mast cell degranulation in the form of cellular mass loss, without the need for dyes or labels. At 
present, HSLCI is best suited for population-level studies in mast cells due to its speed and multi-
sample capacity, while the system’s single-cell tracking capabilities require refinement for this 
cell type due to their rapid drifting in culture vessels. In the course of coming to these 
conclusions, several important observations were made.  
First, the presence of two distinct populations of cells was apparent in every experiment 
conducted. It is unclear what, other than their size and growth behavior, differentiate the two 
groups. Second, significant variation was seen in the median pre-treatment masses of Active 
groups from different batches of mast cells. While all mast cell populations tended to 
consistently exhibit a positively skewed distribution of cell masses, observed medians ranged 
from 150 pg to 350 pg. Priming mast cells with IgE does not seem to contribute significantly to 
this variation  
Third, as previously mentioned, our HSLCI date indicate that mass loss due to DNP-HSA-triggered 
degranulation was only detectable when median pre-treatment masses were greater than 225 
pg. The majority of cell populations measured across our experiments had median masses lower 
than this threshold. However, these same cell populations were successfully triggered using 
DNP-HSA (as measured by IL-6 ELISA), at a variety of cell densities, in the Ryan lab. It is possible 
that these response disparities might stem from a detection limit in our population-level 
approach to measuring mass loss (Figure 26). A second explanation is that there is a minimum 
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biological threshold for degranulation. Perhaps cell size and mass correlates with a measure of 
maturity (i.e. sufficient mediator content) and, therefore, cells that are not mature (i.e. too 
small, insufficient content) will not degranulate in response to FCεRI-mediated activation. This 
explanation would fit with our data, but would need to be borne out using additional assays for 
degranulation in light of the positive IL-6 ELISA. 
  
Fourth, RBL-2H3 cells consistently exhibited a rapid recovery of mass (~90 minutes) following 
degranulation. Regardless of the cause, RBL-2H3 cells behave differently from murine BMMC-
Figure 26. Proposed model of mast cell degranulation. Two distinct sub-populations of 
mast cells (“Active” and “Static”) were detected by LCI and HSLCI. Ovals represent the 
respective range of cell masses and sizes measured in our data. Static cells do not grow or 
respond in any detectable way to DNP-HSA. Active cells grow throughout each experiment 
and, in some cases, exhibit mass loss and subsequent recovery in response to DNP-HSA.  
Green arrows represent the change in mass and area of cells in the Active group in 
response to DNP-HSA, when mass loss was detected. Based on our data, we hypothesize 
that there is either an LCI detection limit and/or biological threshold of ~200 pg, below 
which degranulation (in terms of mass loss) cannot be measured and/or does not occur. 
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derived mast cells. As the tumor line is a familiar presence in mast cell research laboratories, a 
more thorough understanding of its biology is warranted.  
Mast cells play a multifaceted role of in allergy and disease.  Providing a means by which to 
assess degranulation, in addition to understanding the mechanisms that underlie the process, is 
important for basic and translational research. These studies raise important questions about the 
way in which degranulation is measured, and the effect that population variations, natural or 
otherwise, affect the outcome of experiments.  
5.2.5 Methods 
Mast cells 
All mast cells were provided by and obtained from Dr. Ryan’s laboratory at Virginia 
Commonwealth University. Unless otherwise noted, cells were derived by the Ryan lab using a 
Black 6 genetic background. Briefly, bone marrow cells are harvested from the femurs of the 
mice. These cells are cultured with Interleukin 3 (IL-3) and Stem cell factor (SCF) for four to six 
weeks, resulting in their differentiation into mast cells. These differentiated cells are 
subsequently viable for experiments for up to eight weeks when maintained with continuous 
supplementation of IL-3 and SCF in RPMI culture medium.  
Triggering Agents 
Cells triggered using DNP-HSA were first “primed” overnight using 100 ng/ml of mouse anti-DNP 
IgE. Media was exchanged and cells washed prior to experimentation and exposure to DNP-HSA. 
Cells triggered using Ionomycin did not require priming and, therefore, only a media 
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exchange was necessary prior to experimentation (Figure 27). Stocks of all triggering agents and 
media were prepared and provided by the Ryan lab.  
Population-level Dose Response Studies using LCI 
Initially, population-level investigations of mast cell degranulation utilized the first iteration of 
the LCI system. Mast cell responses to Ionomycin and DNP-HSA were assessed at multiple time 
intervals and across a range of doses. In our inaugural experiments, cells were imaged by the LCI 
in a custom, 4-well Teflon sample block. Briefly, two 20 mm x 20 mm hand-cut silicon squares 
were prepared from silicon wafers and cleaned with 70% ethanol. One silicon square was placed 
in the center of each of two wells, designated Control or Treatment, in the Teflon block. 3mL of 
cells suspended in culture medium (5 x 105 cells/ mL) was then added directly to each of the two 
wells.  An optical imaging window was placed on top of each of the silicon chips.  
Figure 27. Summary of triggering agent 
mechanisms of action. Ionomycin and 
DNP-HSA were used independently to 
trigger degranulation in BMMCs. 
Ionomycin is a calcium ionophore 
capable of trafficking calcium directly 
through mast cell membranes. DNP-
HSA binds to FcεRI -bound IgE 
molecules, triggering FcεRI crosslinking 
that results in a signaling cascade. This 
signaling cascade causes the release of 
calcium sequestered in the 
endoplasmic reticulum. Degranulation 
is triggered in both cases as a result of 
the rapid increase in intracellular 
calcium levels (Adapted from Nirmal et 
al., 2013) 
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Response kinetics were measured in response to a 1X (1 nM) dose of Ionomycin. Cells in the 
Treatment well were measured prior to dosing to establish a baseline distribution of population 
cell masses. Ionomycin was administered after these baseline mass measurements, followed by 
additional measurements every 5 minutes for 25 minutes. Imaging of the Control well was 
conducted similarly, with the administration of a media vehicle control (6 μl) in place of 
Ionomycin. Three replicates of this experiment were conducted.  
Follow-on experiments examined our ability to resolve responses across a wide range of 
Ionomycin doses. To accommodate an increased number of samples, cells were imaged on a 
modified Teflon sample block (Figure 28-A). Three standard glass microscope slides () were 
painted matte black and arrayed in parallel on the Teflon block’s surface. 20 mm x 20 mm hand-
cut squares were prepared from silicon wafers, cleaned with 70% ethanol, and arrayed in a 2x3 
grid pattern. 0.25 mm thick plastic shims were placed on top of each silicon chip. Number X glass 
cover glass squares were then placed on top of each shim. The effective imaging area for each 
sample using this arrangement of components was approximately 200 mm2. Mast cell responses 
to Ionomycin were assessed across a log scale of doses (Figure 28-B). Briefly, 1 x 106 unprimed 
mast cells were deposited on to each silicon chip and covered with cover glass. Pre-treatment 
mass measurements were collected from each dosing group’s sample. Ionomycin was then 
added to all samples at indicated doses and allowed to take effect for five minutes. Four images 
at different locations within the sample well were taken for each dose condition. After 
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each dose group had been imaged, the imaging process was repeated for a second cycle. 
Replicates of this experiment were performed three times. The order of imaging for dosing 
groups was randomized for each replicate. These time interval and log-scale dose response 
experiments were repeated, each in triplicate, with DNP-HSA (1X = 50 ng/mL) as a triggering 
agent instead of Ionomycin. 
Effects of IgE Priming on Mast Cell Mass 
Investigations of Primed vs. Unprimed mast cells consisted of comparing cells from the same 
initial population of mast cells. A group of viable cells was split and one half primed (as 
previously described). The next day, cells from both groups were deposited and imaged on the 
Figure 28. LCI sample mount and dosing overview. A) Three standard glass microscope 
slides were painted matte black and arrayed in parallel on the surface of the Teflon block’s 
surface. 20 mm x 20 mm hand-cut squares were prepared from silicon wafers, cleaned 
with 70% ethanol, and arrayed in a 2x3 grid pattern. 0.25 mm thick plastic shims were 
placed on top of each silicon chip. Number X glass cover glass squares were then placed on 
top of each shim. The effective imaging area for each sample using this arrangement of 
components was approximately 200 mm2.  B) Schematic of the sample imaging order and 
dosing used in a single Ionomycin response assay replicate. 
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modified, six-sample Teflon block (approximately 1500 cells measured per group). This was 
repeated three times, with each replicate occurring on a different day.   
Validation of LCI Measurement Reproducibility 
Reproducibility validation experiments utilized fresh unprimed mast cells. 2 mL of 5 x 105 cells/ 
mL cell suspension was pipetted on to each of six silicon chips on the modified Teflon block and 
covered with cover glass, as previously described. Four images were collected of each chip. 
Immediately following this first imaging cycle, a second identical cycle was performed. This 
experiment was performed in triplicate using different populations (different isolation days) of 
mast cells.  
Measurement reproducibility was further assessed by imaging fresh untreated cells on a single 
silicon chip. 2 mL of 5 x 105 cells were deposited onto the chip and covered with cover glass, as 
previously described. 25 images (5x5 grid pattern) were collected. After this first cycle, an 
additional five imaging cycles were performed on the same sample. Three replicates of this 
experiment were conducted, each using a different population of mast cells.  
Single-Cell Degranulation Studies Using LCI  
Experiments involving single-cell tracking utilized 35 mm, single-well, glass-bottomed dishes, 
unless otherwise noted. A custom double-dish mount was constructed to enable the 
simultaneous use of up to two of these dishes (i.e. Control and Treatment). Additionally, all mast 
cell experiments described from this point forward utilized a Phasics camera to acquire mass 
measurements (as opposed to the modified Michelson interferometer described previously).  
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Proof-of-concept cell immobilization studies were conducted using 2.5 ml of fresh untreated 
mast cells suspended to a final concentration of 5 x 105 cells/mL in a 1% methylcellulose solution 
prepared using complete RPMI culture medium. A 4x4 grid of images was collected by the LCI 
every 10 minutes for 16 hours. Phase images were processed as previously described to 
generate mass measurements for individual mast cells. 
Fluorescent imaging studies (summary provided in Supplementary Table 3) designed to correlate 
mass loss events with degranulation were performed as follows. 2.5 mL of fresh untreated mast 
cells were aliquoted and 1X concentrations of YoPro1 (YP1) and Propidium Iodide (PI) were 
added. A 1% methylcellulose solution was prepared using complete RPMI culture medium. Dyed 
cells were suspended in the solution to a final concentration of 5 x 105 cells / ml. This cell 
suspension was transferred to a single 35 mm glass-bottomed dish and incubated under 
standard cell culture conditions for one hour. After incubation, the dish was transferred to the 
LCI. Image collection was initiated in a 2 x 2 grid, with brightfield, fluorescent, and phase images 
being collected in rapid succession at each location. Ionomycin was administered to the sample 
at 1X after approximately 20 minutes of imaging. Post-dosing, imaging continued for eight hours. 
Three replicates of this experiment were performed. Variations of this experiment were also 
conducted using DNP-HSA instead of Ionomycin.  
Phase images from these fluorescent imaging studies were processed as previously described to 
generate mass measurements for individual mast cells. Fluorescent images were separated into 
individual RGB channels, with each channel being subsequently analyzed to track intensity over 
time for regions of interest identified by MATLAB’s otsu thresholding function.  
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Experiments with the adherent rat basophilic leukemia cell line RBL-2H3 were performed as 
follows. RBL-2H3 cells were obtained from the Ryan lab and immediately deposited in provided 
culture medium to a final concentration of 2 x 105 cells/mL in two glass-bottomed dishes. Dishes 
were placed in a cell culture incubator overnight to allow time for cell adherence to the dish 
surface. After incubation, dishes were transferred to the LCI system and allowed to reach 
thermal equilibrium for one hour. After one hour, 4x4 grids of images were collected from each 
dish every 15 minutes for one hour, at which point one of the dishes received a 1X dose of DNP-
HSA. After dosing, cells were imaged for an additional 36 hours. This experiment was repeated 
twice. 
Measurement of Degranulation and Recovery 
Experiments investigating the population-level mass kinetics of degranulation in response to 
DNP-HSA were conducted as follows. Mast cells were primed overnight with IgE (as previously 
described) by the Ryan lab. 3mL of primed cells in culture medium were deposited into each well 
of a 24-well plate at a final concentration of 5 x 105 cells/mL. The plate was placed in the HSLCI 
and allowed to reach thermal equilibrium for one hour. Imaging was conducted at a rate of 30 
images/well every eight minutes for one hour, with plate tilting every 10 minutes. After one 
hour, half of the wells in the plate were dosed with 1X (50ng/mL) DNP-HSA. After dosing, 
imaging continued for an additional 39 hours. Replicates of this experiment were performed 
seven times with moderate variations, including the simultaneous measurement of different 
batches of primed cells or the inclusion of an unprimed population from which primed cells were 
generated. Data generated by the experiments were filtered using manually-implemented 
cutoffs for cell mass and area to remove spurious data points. 
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5.3 Kinetics of KSHV Lytic Activation 
Kaposi’s sarcoma (KS) is an incurable cancer associated with immunosuppression or 
immunodeficiency, often occurring in patients with AIDS or those who have undergone organ 
transplantation.186 It typically effects the skin, but can occur in the lymph nodes, gastrointestinal 
tract, and major organs.187 The primary cause of KS is infection with human herpesvirus-8 (HHV-
8), also known as Kaposi’s sarcoma-associated herpesvirus (KSHV), which is commonly 
transmitted via saliva.188 Briefly, after infecting host cells, KSHV’s latency program is activated by 
default, resulting in the production of several important proteins that interfere with host p53 
and retinoblastoma protein activity, ultimately compromising the cells’ genetic integrity.189,190 
Certain signals can also activate the virus’ lytic program, during which it makes thousands of 
infectious copies of itself and eventually destroys the host cell.191–193 KSHV is a particularly 
interesting because of its possession of numerous human genes, its strong association with 
multiple cancers, and its shared membership in the same viral family as Epstein-Barr virus.194 
In collaboration with the Dr. Blossom Damania’s laboratory at the University of North Carolina’s 
Lineberger Cancer Center, we conducted pilot studies on genetically-modified Kaposi’s Sarcoma 
cells in an effort to evaluate HSLCI as a tool for studying the kinetics of lytic program activation in 
KSHV. Our studies used iSLK.219 cells, a genetically engineered endothelial cell line containing 
Doxycycline-inducible latent KSHV.195 These cells also contain two fluorescent markers: green 
fluorescence protein (GFP), which is constitutively expressed, and red fluorescent protein (RFP, 
which is expressed exclusively during lytic replication of KSHV.  All cells, media, and reagents 
were provided by the Damania lab. 
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Using this model, we aimed to study mass kinetics of iSLK.219 cells immediately after exposure 
to KSHV-inducing Doxycycline. Briefly, 2 mL of 5 x 104 cells were dosed with Doxycycline (1 
μg/ml) and imaged by HSLCI for 65 hours (once every 15 minutes); both phase and fluorescent 
images were collected. Based on this approach, we would expect to see green fluorescence in 
individual cells which transitions to yellow as KSHV lytic programs are activated and RFP 
expression begins. This experiment was repeated three times (navg= 600 cells/experiment).  
Several interesting trends were observed. First, as measured by the emergence of red 
fluorescence, approximately 20-24 hours is required for Doxycycline to induce KSHV’s lytic 
program. Second, three hours after lytic activation, cell growth ceased. This “static” period lasted 
for approximately 30 hours, followed by a slow loss of mass and, finally, cell death. A 
representative single-cell example of these observations is provided in Figure 29. 
In addition to fulfilling their role as a proof of concept for our ability to conduct multi-day 
fluorescent imaging runs, these experiments show that, at least in KSHV, lytic activation has a 
distinct kinetic signature. This has implications for basic virology research as changes in cell 
growth patterns can give clues to the involvement of specific pathways during the latent-lytic 
switch. Further, it could provide a label-free metric of lytic activation for wild type cells. Beyond 
KSHV, HSLCI could be used to study the kinetics of primary infection in across a range of viruses 
and cell types. 
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Figure 29. Single-cell Doxycycline-induced KSHV lytic activation. A representative plot of cell 
mass versus time for a single iSLK.219 cell dosed at 0 minutes with Doxycycline. Individual 
point coloration indicates the fluorescence color emitted by the cell (i.e. yellow indicates 
simultaneous GFP and RFP expression, black indicates a lack of fluorescence). Note: iSLK.219 
cells constitutively express GFP and contain latent, Doxycline-inducible KSHV virus. Induction 
of the virus’ lytic program with Doxycycline also induces RFP expression. 
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Chapter 6 
Conclusions and Future Directions 
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6.0 Chapter Overview 
This chapter provides a summary of the work presented thus far, an overview of ongoing HSLCI 
experiments, and a discussion of future directions. 
6.2 Summary of Work Presented 
Cell mass is emerging as an important indicator of cell health and status. Improvements in digital 
imaging and processing technologies have enabled quantitative phase imaging to become a 
precise method for non-invasively studying cell mass kinetics at the single-cell level. Our work 
using the LCI and HSLCI systems has resulted in several important achievements. First, we have 
demonstrated an ability to measure cells continuously for over 10 days. This is significantly 
longer than similar QPI-based techniques and provides a sufficient window of time to observe 
the vast majority of cellular processes. Second, we have demonstrated an ability to handle a 
range of sample types on the same instrument, including single cells and clusters, non-adherent 
and adherent cells, and established cell lines and patient samples. Third, the HSLCI has enabled 
us to visualize unique mast cell populations and processes, as well as confirmed our ability to 
conduct correlative fluorescent studies. Fourth, our work with melanoma validated LCI and HSLCI 
in two independent laboratories. We demonstrated an ability to quantify heterogeneous 
responses to therapeutics and discriminate between drug-sensitive and drug-resistant cells in 
multiple patient-derived melanoma cell lines, adding to the body of evidence that the in vitro 
measurement of cell mass after drug exposure can achieve the resolution and throughput 
necessary to be clinically relevant. Finally, our pioneering work on T cell mass dynamics during 
immune reconstitution revealed previously undescribed kinetics that could be informative in 
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tailoring post-transplant immunosuppression. In summary, we have developed, validated, and 
deployed a microscopy platform that has the potential to become a powerful tool in applications 
from the bench to the bedside. 
6.3 Ongoing Work 
Work by several members of the Reed laboratory, including Graeme Murray and Daniel Guest, 
have resulted in numerous improvements in HSLCI system performance (enabling imaging 
speeds of 16 fps, 4X faster than described in our work on melanoma) and an expansion of its 
applications. The following sub-sections describe ongoing HSLCI pilot projects. 
6.3.1 Drug-Induced Cellular Senescence 
Senescence, is a protective and stable state in which the cell cycle has been arrested in response 
to a variety of signals, including telomere shortening, drug exposure, and the expression of 
growth-promoting oncogenes.196 For previously-healthy cells, entering a senescent state can 
help prevent the development of malignancies.197 In cancer cells, senescence induced by 
chemotherapy or radiation treatments can have the opposite effect: promoting aggressive drug-
resistant phenotypes.198,199 As such, the characterization and quantification of therapy-induced 
senescence is and urgent and important area of research for improving patient outcomes.   
In collaboration with Dr. David Gewirtz in the VCU Department of Pharmacology and Toxicology, 
our lab is conducting pilot studies on the mass kinetics of drug-induced senescence in cancer 
cells. Briefly, H460 (lung carcinoma) cells are exposed to Etoposide, a chemotherapeutic used in 
the treatment of a range of solid tumor and blood cancers. Following drug exposure, cells are 
sorted into senescent and non-senescent groups by flow cytometry using an established 
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fluorescent marker for cellular senescence (C12FDG, a modified substrate of β-galactosidase).200 
Sorted groups are then imaged by HSLCI for up to six days to measure cell mass and detect 
proliferative recovery. Three replicates of this experiment have been performed, to-date. 
Our data indicate that cells sorted as “senescent” are 3-4X larger in mass and area than both 
control cells and drug-treated cells that did not become senescent. These larger cells, though 
theoretically growth static, exhibited mass accumulation rates of 1% per hour, while non-
senescent treated and control cells grew at approximately 3% per hour. In addition, a small 
percentage of senescent cells eventually transitioned into a rapidly-growing (3% per hour) state 
and, subsequently, divided at three or more days, post-treatment. While further experimental 
replicates are required to confirm the reproducibility of these trends, the data demonstrate our 
ability to detect changes in proliferative states and quantify the heterogeneity of responses in 
senescent lung carcinoma cells. In addition to aiding the characterization of drug-induced 
senescence as a process, this approach could help in screening new and existing therapeutics for 
their propensity to promote drug resistance.201  
6.3.2 Effect of Radiation on Endothelial Cells 
Prostate cancer is the most commonly-diagnosed cancer in men.202 Treatment generally consists 
of classical chemotherapy, hormone ablation, or radiotherapy (targeted radiation).203 Morbidity 
and mortality vary significantly by socioeconomic status, ethnicity, and geographic location.204 
Even taking into account disparities in access to medical care and screening, men of African 
descent have significantly worse outcomes, including higher rates of radiation treatment-
induced side effects like erectile dysfunction and proctitis.205 Single-nucleotide polymorphism 
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(SNP) and genome-wide association studies (GWAS) have both supported these observations.206 
The underlying cause of many of the observed side effects and poor treatment outcomes is 
radiation-induced damage to endothelial cells that make up critical vasculature around the 
prostate.207,208  
In this context, our lab is evaluating HSLCI, in collaboration with Dr. Ross Mikkelsen in the VCU 
Department of Radiation Oncology, as a tool to measure the effects of radiation exposure in 
endothelial cells. These pilot studies utilize EA.hy926 cells, a hybrid cell type that is a fusion of 
drug-resistant lung cancer with human umbilical vein cells.209  Briefly, EA.hy926 cells are exposed 
to a range of radiation does (0, 2, 4, and 8 Gray (Gy)), seeded in a multi-well plate, incubated for 
eight hours, and then observed using HSLCI for 24 hours to measure mass kinetics. This 
experiment has been repeated two times.  
Interestingly, dose-dependent increases in median population mass were observed in treated 
groups. Specifically, while control cells grew and then divided, division in treated populations 
was not observed. Instead, treated cells accumulated mass but did not divide, with the 8 Gy 
group exhibiting the largest median cell masses at 32 hours, post-dosing. Follow-on studies aim 
to reproduce these results while observing cells over a longer time window to detect any cell 
divisions in treated groups. We hope to continue this work by comparing responses of cell lines 
derived from Caucasian and African American patients in an effort to better understand the 
effects of radiation therapy and, potentially, develop markers for the retroactive quantification 
of radiation exposure. 
6.3.3 PDX Models with HSLCI to Study Drug Resistance 
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HSLCI is highly complementary to a powerful emerging clinical research tool: patient-derived 
xenografts (PDX). PDX models maintain the genetic and histologic characteristics of the patient 
from whom they originate.210–213 Therapeutic compound screening in these models can identify 
drugs that are effective in treating tumors from the patients from which they were derived and/or 
for patients with a similar genomic profile. One of the best attributes of PDX models is that they 
are maintained within an in vivo setting from the time they are isolated from a patient. This feature 
conserves cellular heterogeneity by avoiding clonal selection due to 2D culturing on plastic 
surfaces. Further, cell-to-cell variability observed within established cell lines has been well 
documented, and studies with transgenic models have revealed genomic mechanisms that drive 
drug resistance in response to targeted therapeutics.214–216 Pairing HSLCI with PDX models could 
enable the rapid identification of patient-specific efficacious chemotherapeutics. 
We have tested the HSLCI system with patient-derived melanoma, breast, brain, lung, and 
blood cancer cell lines, as well as PDX lines. The platform is unique among biomass 
measurement methods in its combination of sampling depth, speed, and compatibility with 
both adherent and non-adherent cells, single cells and cell clusters. 
An overview of PDX model generation and usage methodologies is shown in Figure 30. Briefly, a 
tumor surgically resected from a cancer patient is disaggregated into a single-cell suspension. 
The suspension is transplanted into an immunodeficient mouse and allowed to grow. After 
sufficient growth, the tumor is removed and transplanted into a second immunodeficient mouse 
for tumor expansion. Expanded tumors can then be utilized in studies or cryopreserved for 
future use.217  
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Successful PDX model generation depends upon the optimization of several parameters, 
including the choice of an appropriate genetic background of immunodeficient mouse and 
selection of transplantation methodology and location. These choices depend both on the type 
of cancer being transplanted and the overall research aims. Specifically, establishment of models 
from primary tumor samples requires mice with a high degree of immunodeficiency and, 
therefore, necessitates the use of mouse strains such as NOD/SCID/IL2rg-/- (NSI), which lack B, 
NK, and T cells. Further, these models are now frequently humanized after transplantation via 
Figure 30. Overview of PDX model generation and usage. Tumor cells from a cancer patient 
are excised, disaggregated, and filtered to yield a single-cell suspension. The suspension is 
injected into an immunodeficient mouse, with or without membrane protein augmentation, 
for engraftment. Cells are most commonly introduced intravenously or subcutaneously. The 
tumor is allowed to expand to a size sufficient for removal and secondary transplantation 
into multiple immunodeficient mice. At this stage, the secondary transplant recipients can be 
used to multiple ends: 1) biological characterization (i.e. tumorigenesis, metastasis), 2) drug 
screening using excised tumor cells, and 3) genetic characterization of tumors via 
sequencing. Results from any of these avenues can be used to inform further studies and, 
ideally, the personalized selection of therapeutics.  
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the infusion of human hematopoietic stem cells to better mimic the human immune 
environment, improving the model’s general relevance. To enhance the likelihood of successful 
tumor establishment, transplantation of cells into these mice is frequently augmented with 
basement membrane proteins (i.e. Matrigel, Corning, Inc.) and/or fibroblasts and endothelial 
cells. Intravenous and subcutaneous (heterotopic) injections are the most common for initial 
implantation due to their relative technical simplicity and ease of monitoring, though organ-
specific (orthotopic) implantation is an option that, theoretically, better mirrors the environment 
of human tumors.  Once established, PDX models are valuable tools for both basic and preclinical 
cancer research. In addition to enabling the study of complex processes like metastasis and 
tumorigenesis, they provide a platform for screening drugs and identifying new therapeutic 
targets, both in vitro and in vivo.218–220 
In collaboration with Dr. Chuck Harrell in the VCU Department of Pathology, we are investigating 
drug responses in PDX models of Triple-Negative Breast cancer (TNBC). Briefly, in 2018, an 
estimated 266,000 women in the United States will be diagnosed with invasive breast cancer 
and ~40,000 will die of the disease.82 The annual death rate due to breast cancer has declined 
over the past several decades due to earlier detection and advances in our understanding of 
the disease’s molecular subtypes, which govern treatment and predict prognosis.221,222 
However, clinical courses and outcomes for this common malignancy remain variable despite 
the use of therapies guided by a combination of clinical assessments that include tumor 
subtyping, clinical grading and staging, and the expression of estrogen (ER), progesterone (PR), 
or amplified HER2/neu cell surface receptors.223,224  
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Accounting for ~15% of all breast cancers, TNBC is a particularly aggressive form of the 
disease that often metastasizes to vital organs, including the brain, bone, liver, and lungs .225–
228 Breast tumors that are genetically characterized as basal-like tumors (most of which are 
TNBC) often metastasize before they are surgically resected.221,222,229 This metastatic 
propensity contributes to the poor prognosis associated with this subtype.230,231  Women with 
TNBC are limited to receiving chemotherapy and, despite highly toxic therapeutic regimens, 
many eventually die from the burden of their disease.93,94,232,233  
Repeated assessments of tumor sensitivity to available therapeutics could improve clinical 
outcomes by staying ahead of developing drug resistance in patients with breast and other 
cancers. Therefore, the main goal of our current collaboration is to determine whether HSLCI 
can predict in vivo PDX drug sensitivity and resistance and, eventually, to assess the ability of the 
HSLCI to characterize mechanisms of tumor heterogeneity in PDX breast cancer models. Over 
the past four years, Dr. Harrell has developed a set of models and methods to study the growth, 
progression, and molecular mechanisms driving drug sensitivity within breast cancer PDX 
models. The focus of our current efforts are PDXs that represent the most aggressive breast 
cancer subtypes. These include TNBCs WHIM2, WHIM30, HCI01, HCI09, and HCI10. Each of the 
PDX models we are investigating has been RNA-Seq expression profiled and analyzed by 
immunohistochemistry for ER, PR, and HER2 status.  Dr. Harrell has experience growing each PDX 
model as mammary tumors and has quantified their growth rates.  
Thus far, we have demonstrated a capability to detect cell growth and death responses in cells 
freshly isolated from the WHIM2, WHIM30, HCI01, HCI09, HCI11, and PT52 TNBC PDX mouse 
models with the HSLCI platform. An example of this drug sensitivity data from two PDX lines is 
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provided in Figure 31, while an example of our ability to resolve drug resistance at the single-cell 
level is provided in Figure 32.  
 
Figure 31. Patient-derived xenograft (PDX) lines PT52 and HCI09 sensitivity to Carboplatin. Data 
for PT52 (Carboplatin-sensitive) is shown in the upper panel. Data for HCI09 (Carboplatin-
resistant) is shown in the lower panel. Each set of boxplots summarizes the hourly growth 
rates of a population of cells exposed to escalating concentrations of Carboplatin during a 
single experimental replicate. Individual dots in the underlying scatter plots represent the 
growth rates of single cells. Boxplot notches are indicative of the 95% confidence intervals for 
the medians. Median population growth rates from all experimental replicates are plotted 
and fit with sigmoid curves. Error bars indicate the 95% confidence intervals for the medians. 
Data adapted from experiments conducted with Graeme Murray in the Reed Lab.  
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Importantly, the drug responses measured to-date match those observed in in vivo studies 
conducted by Dr. Harrell (i.e. tumors sensitive to drug administered  are also sensitive in vitro). 
This data establishes the viability of the sample handling techniques we will use to obtain HSLCI-
measurable results from surgically resected material, and lays the groundwork for large-scale 
studies for quantifying drug resistance and heterogeneity.  
6.4 Future Directions 
Following the efforts described above, additional studies are planned to expand the scope of 
previous experiments and keep pace with emerging trends.  
6.4.1 Three-Dimensional Cell Culture 
While two-dimensional in vitro culturing remains dominant in cancer and drug development 
studies, mounting evidence on the importance of the tumor microenvironment has led to the 
emergence of new three-dimensional techniques that aim to better mimic in vivo conditions.234–
236 Specifically, two-dimensional cultures lack stromal cells and features like the extracellular 
matrix, have altered rates of drug diffusion, and subject cells to different surface textures than 
encountered in the body, all of which can alter behavior and responses to therapeutics.  Tumor 
Figure 32. Single-cell example of PT52 
Carboplatin response heterogeneity. 
HSLCI images of two PT52 cells, each at 
T = 0 min. and T = 600 min., exposed to 
100 uM Carboplatin. Single-cell growth 
tracks of PT52 cells (resistant, red; 
sensitive, blue) shown in HSLCI image. 
Initial and final growth rates for each 
cell are plotted as gray lines. 
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spheroids and organoids are two distinct but similar 3D approaches that have been developed to 
address these concerns.237,238  
There is currently no single standard protocol for developing these 3D models. Spheroids 
typically refer to self-assembled spherical aggregates of cells several hundred microns in 
diameter.239 Creating them involves starting with purified tumor cells (though mixed populations 
can be used) and using a variety of techniques to encourage them to form such assemblages. 
Some methods rely on preventing adhesion to culture vessel surfaces to promote cell clustering, 
while others uses a synthetic extracellular matrix called Matrigel (Corning Life Sciences, Inc.) to 
foster 3D architectures and separate tumor cells from fibroblast feeder layers.240 Others keep 
cells suspended under continuous motion to prevent adhesion; some allow them to sediment to 
the bottoms of individual media droplets. Finally, a whole range of micropatterned surfaces have 
been created to coax cells into various shapes and structures using microfluidics. Organoids 
generally refer to slightly larger, more complex, and more organized clusters of tissue excised 
from a mouse or human using enzymatic and mechanical digestion.241 Once excised, these 
primary organoids are often similarly cultured in Matrigel or collagen. Spheroids and organoids 
can eventually be transferred to traditional multi-well plates for imaging, or cultured in custom 
PDMS molds which allow gas and nutrient diffusion and have refractive indices similar to glass.  
As 3D culture becomes more common, it will be necessary to demonstrate HSLCI’s compatibility 
with spheroids and organoids.242 We have already shown an ability to reliably image cell clumps 
and clusters in two-dimensional culture models. Therefore, the biggest challenge will be the 
acquisition of data from different focal planes. If we aim to simply study whole clusters, 
generating this data requires no modifications to our system because our measurements take 
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into account the entire optical path of the light measured, whether it passes through one cell or 
ten. However, if we hope to maintain single-cell resolution for correlative fluorescent imaging, 
image acquisition approaches similar to those employed by confocal microscopy will be 
considered, in addition to the incorporation of additional QPI modalities like DHM or spatial light 
interference microscopy (SLIM).243 
6.4.2 Large-Scale Patient Studies 
A logical extension of our completed and ongoing experiments is the design of larger scale 
patient studies. For our work in melanoma, HSLCI dose response testing of primary tumor 
samples prior to the administration of therapeutic regimens would enable a comparison of our 
assays’ outcomes with actual patient responses. With this material, we could also begin attempts 
at comparing 2D and 3D culture methodologies in parallel. In addition, these assays could be 
performed for other cancers in which biopsies are straightforward to attain, including breast and 
blood cancers. Other groups have demonstrated success in correlating drug-induced in vitro 
mass changes with therapeutic efficacy in small numbers of patients.57 If HSLCI is to be adapted 
for clinical use, this type of validation will be a mandatory next step. 
Regarding our work in T cells, follow-on studies with larger patient cohorts will enable several 
lines of inquiry. First, considering the small size of our pilot study, we would hope to reproduce 
the trends we observed in our original data and increase the number of control group patients 
(autologous transplant recipients). Second, we hope to identify important T cell subsets that 
could enhance the resolution of our kinetic signatures. Accomplishing this goal requires both 
more patient material and additional resources for requisite analyses. Finally, given the range of 
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diseases that can lead to the need for SCT and the broad demographics of those patient 
populations, a larger cohort would help us account for any effects these variables might 
impart.244  
6.5 Conclusion 
HSLCI shows promise as a powerful and versatile research tool. We have demonstrated its 
compatibility with a wide range of cell types and applications and validated its performance in 
two independent laboratories. At present, HSLCI’s large data footprint is its most significant 
drawback, both in terms of the cost of data storage and time required for processing. Addressing 
this issue is, fortunately, straightforward given the existence of hardware solutions like powerful 
graphics processing units (GPUs) that are better suited to image-based tasks and high-capacity 
solid-state drives (SSDs) capable of rapidly reading and writing data. In addition, minor software 
modifications will streamline data acquisition and analysis, increasing the efficiency of storage 
and processing times. These improvements, coupled with our laboratory’s ongoing work and 
planned studies, will enable HSLCI to continue contributing to the understanding of mass kinetics 
and their importance in biology and medicine.  
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Supplementary Figures 
 
 
 
Supplementary Figure 1. 24-Well Plate Topography Topography of a typical 24-well glass-
bottomed plate, displayed in terms of the relative z position (um) of the HSLCI microscope’s 
objective. Z-position at any point is indicative of “best focus”zzz as determined by the 
platform’s automated focusing feedback loop. The feedback loop detects changes in the 
distance between the plate bottom and the microscope objective hundreds of times per 
second, adjusting a piezo to which the microscope objective is mounted to maintain best 
focus throughout lateral scanning of the sample 
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Supplementary 
Figure 2. 7-day 
proliferation assay. 
Live cell counts by 
day, normalized to 
day 0.  All three 
melanoma sensitive 
and resistance 
paired cell lines 
were exposed to 
increasing doses of 
Vemurafenib, or 
vehicle (0.1% 
DMSO) and media 
controls. A 
representative 
experiment is shown 
(n = 3). 
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Supplementary Figure 3.  Example distributions of single cell growth rates over time.  A) M249P 
parental line grown in DMEM. B) M249R4 resistant line under treatment with 5𝜇M of 
Vemurafenib. C) GFP-M249R4 under treatment with 5𝜇M of Vemurafenib.  Hourly growth 
rates are estimated by linearly fitting selected single cell data points that were collected 
within each hour of the experiment for a span of 24 hours. Single cell tracks were quality 
controlled using a upper cutoff of 1.5% standard deviation of residuals in linear regression.  
Due to the short time window, there is larger error in the estimation of growth rates than in 
data shown in Figures 19-21. 
Supplementary Figure 4.  Detecting minority 
resistant cells in a mixed population.  Example 
biomass versus growth rate data from a 10:1 
M249P (sensitive; blue) : M249R4-GFP (resistant; 
red) cell mixture exposed 5μM Vemurafenib for 48 
hours. Cell identities are marked by fluorescence 
signals. 
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Supplementary Tables 
Supplementary Table 1.  Patient-Derived Melanoma Lines 
Cell Line Designation Molecular Lesions 
M229P BRAF V600E 
M229R5 BRAF V600E, PDGFR up-regulation 
M238P BRAF V600E 
M238R1 BRAF V600E, PDGFR up-regulation 
M249P BRAF V600E 
M249R4 BRAF V600E, N-RAS Q(61)K 
 
Supplementary Table 2.  Kinase Inhibitor Dosing Chart 
Trade Drug Chemical Clinical Dose Target 
Serum Conc. 
(ng/mL) μM (1x) 
Tafinlar Dabrafenib GSK2118436 150 mg twice daily BRAF 1050 2.02 
Cotellic Cobimetinib GDC-0973 / RG7420 60 mg once daily MEK1 273 0.51 
N/A Selumetinib AZD6244 / ARRY-142886 75 mg twice daily MEK1 1165 2.55 
Mekinist Trametinib GSK1120212 2 mg once daily MEK1/2 22.2 0.04 
N/A Binimetinib MEK162 / ARRY-162 45 mg twice daily MEK1/2 257.0  0.58 
 
Supplementary Table 3. Mast Cell Fluorescence Experiments 
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Supplementary Methods 
M249R4-GFP cell generation.  Third generation lentiviral construct pMD.G (VSV-G envelope) was 
used in combination with pMDLg/pRRE (gag/pol elements) and pRSV-REV. Lentivirus was 
produced by transient plasmid co-transfection into HEK293T cells. Infections used protamine 
sulphate, with mGFP subcloned into the FUGW vector. M249R4 GFP-positive cells were obtained 
using a BD FACSAria sorter. GFP expression was determined 4 days after sorting by a BD LSRII flow 
cytometer. FACS Diva analysis showed 98.4% of M249R4-GFP cells express mGFP.  
Drug Sourcing and Preparation. Imatinib (Cat.# S1026), Dabrafenib (Cat.# S2807), Selumetinib 
(Cat.# S1008), Trametinib (Cat.# S2673), Cobimetinib (5mg, Cat.# S8041) and Binimetinib (10mg, 
Cat.# S7007) were purchased from Selleck Chemicals (Houston, TX). Imatinib, Vemurafenib, 
Dabrafenib, Selumetinib, and Trametinib were supplied at 10mM in DMSO. Cobimetinib and 
Binimetinib were supplied as dry powders but suspended in DMSO to a final stock concentration 
of 10mM upon receipt. 
Kinase Inhibitor 1X Dose Determination: For each inhibitor, a “1X” dose was calculated. Briefly, 
clinical doses were obtained from publically-available package inserts or, if none were available, 
the median dose administered in clinical trials. Doses were matched to peak serum concentration 
values (Cmax (ng/mL)) for each inhibitor as measured in clinical trials in which the doses were 
utilized. If multiple Cmax values were available, those values were averaged to yield a single peak 
serum concentration value. Using each drugs’ molecular weight, peak serum concentration values 
were converted to micromolar (μM) units and designated as “1X”.  Unless otherwise noted, clinical 
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doses were sourced from package inserts and used to identify Cmax values in studies. References 
for Cmax determinations: imatinib 4-6, dabrafenib 7-8, Cobimetinib 9, Selumetinib 10-13 (dose 
determined from median of clinical trial doses), Trametinib 14, and Binimetinib 15-16 (dose 
determined from median of clinical trial doses). 
Cell proliferation assay. Cells in multiple six-well tissue culture plates were incubated overnight at 
37oC, 5% CO2.  Each six-well plate contained one well with a media control, one well with 0.1% 
DMSO vehicle control, and four wells of Vemurafenib at 1 μM, 3 μM, 5 μM, or 10 μM 
concentrations. Cells were counted each day for five days following seeding. 
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